nucleic
acid
na
amplif
techniqu
commonli
use
diagnos
manag
patient
infecti
diseas
growth
number
food
drug
administrationeapprov
test
kit
analytespecif
reagent
facilit
use
technolog
clinic
laboratori
technolog
advanc
na
amplif
techniqu
autom
na
sequenc
multiplex
analysi
reinvigor
field
creat
new
opportun
growth
simpl
samplein
answerout
molecular
test
system
wide
avail
deploy
varieti
laboratori
clinic
set
molecular
microbiolog
remain
lead
area
molecular
patholog
term
number
test
perform
clinic
relev
nabas
test
reduc
depend
clinic
microbiolog
laboratori
tradit
antigen
detect
cultur
method
creat
new
opportun
laboratori
impact
patient
care
chapter
review
na
test
appli
specif
pathogen
infecti
diseas
syndrom
focu
diseas
na
test
consid
standard
care
highlight
uniqu
challeng
opportun
test
present
clinic
laboratori
frederick
nolt
background
nucleic
acid
na
amplif
techniqu
commonli
use
diagnos
manag
patient
infecti
diseas
growth
number
food
drug
administrationeapprov
test
kit
analytespecif
reagent
facilit
use
technolog
clinic
laboratori
technolog
advanc
na
amplif
techniqu
autom
na
sequenc
multiplex
analysi
reinvigor
field
creat
new
opportun
growth
simpl
samplein
answerout
molecular
test
system
wide
avail
deploy
varieti
laboratori
clinic
set
molecular
microbiolog
remain
lead
area
molecular
patholog
term
number
test
perform
clinic
relev
nabas
test
reduc
depend
clinic
microbiolog
laboratori
tradit
antigen
detect
cultur
method
creat
new
opportun
laboratori
impact
patient
care
chapter
review
na
test
appli
specif
pathogen
infecti
diseas
syndrom
focu
diseas
na
test
consid
standard
care
highlight
uniqu
challeng
opportun
test
present
clinic
laboratori
sinc
public
fifth
edit
textbook
signific
chang
occur
practic
diagnost
molecular
microbiolog
nucleic
acid
na
amplif
techniqu
commonli
use
diagnos
manag
patient
infecti
diseas
growth
number
food
drug
administr
fda
eapprov
test
kit
analytespecif
reagent
asr
facilit
use
technolog
clinic
laboratori
technolog
advanc
na
amplif
techniqu
autom
na
sequenc
multiplex
analysi
reinvigor
field
creat
new
opportun
growth
simpl
samplein
answerout
molecular
test
system
wide
avail
deploy
varieti
laboratori
clinic
set
molecular
microbiolog
remain
lead
area
molecular
patholog
term
number
test
perform
clinic
relev
nabas
test
reduc
depend
clinic
microbiolog
laboratori
tradit
antigen
detect
cultur
method
creat
new
opportun
laboratori
impact
patient
care
chapter
review
na
test
appli
specif
pathogen
infecti
diseas
syndrom
focu
diseas
na
test
consid
standard
care
highlight
uniqu
challeng
opportun
test
present
clinic
laboratori
complet
current
list
fdaclear
fdaapprov
microbi
na
base
test
found
http
wwwfdagovmed
devicesproductsandmedicalproceduresinvitrodiagnost
reader
direct
molecular
microbiolog
diagnost
principl
practic
edit
comprehens
depth
examin
dynam
excit
disciplin
human
immunodefici
viru
caus
agent
acquir
immunodefici
syndrom
aid
rna
viru
belong
genu
lentiviru
famili
retrovirida
replic
viru
complex
involv
revers
transcript
rna
genom
doublestrand
dna
molecul
proviru
integr
host
genom
enter
cell
use
receptor
coreceptor
gener
coreceptor
found
macrophag
coreceptor
found
cell
determin
cellular
tropism
viru
becom
import
antiretrovir
drug
target
coreceptor
revers
transcriptas
rt
enzym
proofread
capabl
lead
signific
genet
divers
sever
distinct
genet
subtyp
clade
identifi
categor
three
group
major
outlier
n
nonmajor
nonoutli
recent
new
group
p
identifi
close
relat
gorilla
simian
immunodefici
viru
major
group
divid
nine
clade
aek
circul
recombin
form
crf
determin
basi
sequenc
divers
within
gag
env
gene
group
viru
found
worldwid
clade
b
predomin
europ
north
america
clade
c
africa
india
clade
e
much
southeast
asia
complex
replic
cycl
genet
divers
two
import
factor
influenc
design
interpret
molecular
assay
manag
patient
infect
transform
test
perform
measur
concentr
rna
blood
viral
load
test
test
resist
antivir
drug
tool
possibl
maxim
effect
antiretrovir
therapi
art
individu
first
viral
load
test
approv
fda
rapidli
becam
standard
care
monitor
respons
art
earli
studi
found
patient
higher
viral
load
progress
rapidli
aid
death
low
viral
load
viral
load
test
wide
accept
marker
respons
art
guidelin
initi
therapi
base
viral
load
chang
understand
diseas
progress
higher
cell
count
improv
avail
newer
potent
less
toxic
drug
art
recommend
hivinfect
individu
regardless
cell
count
viral
load
dhh
panel
antiretrovir
guidelin
http
aidsinfonihgov
treatment
initi
viral
load
test
crucial
monitor
respons
therapi
measur
hivinfect
individu
time
entri
care
therapi
initi
regular
interv
usual
month
therapi
standard
care
treat
combin
antiretrovir
drug
classifi
base
viral
target
nucleosid
revers
transcriptas
inhibitor
nrti
nonnucleosid
revers
transcriptas
inhibitor
nnrti
proteas
inhibitor
pi
fusion
inhibitor
integras
inhibitor
also
known
integras
strand
transfer
inhibitor
insti
entri
inhibitor
current
depart
health
human
servic
panel
antiretrovir
guidelin
http
aidsinfonih
govguidelin
recommend
initi
regimen
two
nrti
nnrti
pi
insti
pretreat
viral
load
valu
influenc
treatment
regimen
regimen
less
effect
patient
high
viral
load
initi
appropri
therapi
typic
log
greater
decreas
viral
load
within
month
goal
patient
achiev
viral
load
limit
detect
sensit
assay
copiesml
data
shown
lower
absolut
viral
load
better
clinic
virolog
outcom
guidelin
recommend
quantifi
plasma
rna
immedi
initi
therapi
week
later
goal
achiev
undetect
viral
load
level
within
week
initi
therapi
import
determin
earli
treatment
cours
suboptim
viral
load
suppress
factor
affect
adher
assess
need
regimen
alter
initi
respons
character
viral
load
monitor
everi
month
ensur
respons
therapi
sustain
note
viral
blip
defin
detect
viral
load
usual
copiesml
occur
success
treat
individu
predict
virolog
failur
reason
virolog
failur
defin
sustain
viral
load
copiesml
viral
load
test
also
aid
diagnosi
acut
infect
window
period
infect
occur
detect
antibodi
product
although
current
avail
viral
load
assay
fda
approv
diagnost
purpos
period
earli
infect
patient
typic
high
viral
load
rang
copiesml
hiv
rna
test
recommend
updat
hiv
diagnost
test
algorithm
patient
reactiv
fourthgener
immunoassay
test
neg
supplement
antibodi
differenti
test
primarili
better
detect
acut
infect
howev
one
hiv
rna
test
fda
approv
diagnosi
aptima
qualit
assay
holog
san
diego
ca
wide
avail
clinic
laboratori
hospit
laboratori
would
benefit
fda
diagnost
claim
viral
load
test
done
reflex
diagnost
algorithm
verifi
claim
local
laboratori
level
overli
burdensom
provir
dna
test
amplicor
dna
polymeras
chain
reaction
pcr
roch
diagnost
avail
research
use
ruo
test
help
neonat
born
mother
receiv
art
antiretrovir
agent
matern
antibodi
cross
placenta
antiretrovir
agent
suppress
replic
viru
neonat
rna
test
fals
neg
earli
birth
matern
antibodi
persist
neonat
year
birth
therefor
reliabl
marker
neonat
infect
current
three
commerci
avail
fdaapprov
viral
load
assay
two
assay
use
realtim
pcr
coba
ampliprepcoba
taqman
version
roch
diagnost
realtim
system
abbott
molecular
third
versant
rna
siemen
use
branch
dna
signal
amplif
amplif
method
gene
target
dynam
rang
assay
given
tabl
newli
emerg
na
amplif
test
naat
platform
potenti
true
pointofcar
test
hiv
rna
sever
eg
aler
biohelix
cepheid
iquumroch
commerci
develop
test
may
applic
detect
acut
infect
confirm
screen
test
determin
viral
load
resourcepoor
set
clinic
laboratori
use
one
realtim
pcr
assay
lower
limit
detect
quantif
increas
dynam
rang
compar
oldergener
pcr
assay
branch
dna
assay
genotyp
bia
signific
problem
earlier
viral
load
assay
gene
target
chosen
highli
conserv
among
differ
subtyp
howev
problem
address
current
version
roch
abbott
realtim
pcr
assay
accur
quantifi
group
group
crf
intraassay
imprecis
viral
load
assay
approxim
log
copiesml
biolog
variat
viral
load
patient
receiv
therapi
approxim
log
copiesml
consequ
chang
viral
load
must
exceed
log
copiesml
threefold
chang
suggest
meaning
chang
viral
replic
viral
load
test
routin
perform
plasma
specimen
ethylenediaminetetraacet
acid
edta
anticoagul
choic
acidecitrateedextros
also
accept
anticoagul
blood
anticoagul
heparin
unaccept
test
critic
handl
clinic
specimen
properli
minim
risk
rna
degrad
specimen
collect
transport
plasma
separ
within
hour
collect
ideal
store
c
although
plasma
viral
rna
stabl
c
sever
day
laboratori
test
specimen
collect
remot
site
sampl
handl
requir
care
attent
special
blood
collect
contain
tube
avail
contain
gel
provid
physic
barrier
plasma
cell
centrifug
tube
ship
without
need
transfer
plasma
separ
tube
tube
frozen
pour
plasma
may
lead
fals
elev
viral
load
assay
six
gener
class
antiretrovir
drug
use
clinic
care
nrti
nnrti
pi
fusion
inhibitor
insti
entri
inhibitor
viral
resist
occur
drug
class
particularli
viral
replic
maxim
suppress
therapi
current
standard
care
use
regimen
contain
combin
drug
resist
less
like
occur
complex
regimen
monotherapi
clinic
util
antivir
resist
test
infect
individu
well
establish
regularli
updat
guidelin
use
found
http
aidsinfonihgov
current
dhh
panel
antiretrovir
guidelin
recommend
resist
test
perform
follow
situat
initi
art
patient
guid
select
activ
drug
chang
antiretrovir
regimen
manag
suboptim
viral
load
reduct
pregnant
women
initi
therapi
resist
test
done
genotyp
phenotyp
method
genotyp
assay
identifi
specif
mutat
nucleotid
chang
associ
decreas
suscept
antivir
drug
phenotyp
assay
perform
creation
pseudovir
vector
measur
replic
capac
vari
concentr
drug
compar
replic
wildtyp
viru
genotyp
phenotyp
method
use
clinic
assess
antivir
resist
patient
phenotyp
test
usual
reserv
drugexperienc
patient
complic
resist
profil
discuss
limit
autom
sequenc
method
genotyp
resist
method
use
often
inform
treatment
decis
current
avail
fdaclear
assay
detect
mutat
rt
proteas
gene
modif
exist
assay
need
detect
resist
mutat
associ
class
drug
integras
fusion
inhibitor
first
step
genotyp
assay
isol
rna
plasma
follow
revers
transcriptas
polymeras
chain
reaction
rtpcr
amplif
sequenc
rt
proteas
gene
analysi
result
involv
sequenc
align
edit
mutat
identif
comparison
wildtyp
sequenc
interpret
clinic
signific
mutat
identifi
clinic
laboratori
perform
genotyp
resist
test
reli
commerci
assay
provid
reagent
softwar
program
assist
interpret
result
two
assay
clear
fda
trugen
genotyp
kit
opengen
dna
sequenc
system
siemen
healthcar
diagnost
viroseq
genotyp
system
abbott
molecular
interpret
genotyp
resist
test
complex
interpret
resist
mutat
use
rulesbas
softwar
take
account
crossresist
interact
mutat
commerci
avail
system
gener
summari
report
list
variou
mutat
identifi
rt
proteas
gene
drug
report
resist
possibl
resist
evid
resist
insuffici
evid
comprehens
discuss
specif
mutat
associ
antiretrovir
drug
interact
mutat
beyond
scope
chapter
avail
varieti
sourc
eg
http
wwwiasusaorg
http
hivdbstanfordedu
limit
current
use
genotyp
phenotyp
assay
detect
mutant
make
least
total
viral
popul
regimen
chosen
base
resist
test
may
alway
effect
minor
popul
quickli
predomin
presenc
drug
drug
select
pressur
also
need
resist
mutat
persist
detect
concentr
viral
popul
drug
therapi
discontinu
wildtyp
viru
may
quickli
predomin
reason
recommend
specimen
resist
test
obtain
patient
art
minimum
viral
load
requir
reliabl
resist
test
approxim
copiesml
genotyp
assay
especi
sensit
rna
degrad
care
must
taken
properli
handl
specimen
collect
utr
genom
structur
similar
virus
famili
flavivirida
includ
mani
arthropodborn
virus
flavivirus
three
ntermin
protein
hcv
core
envelop
envelop
probabl
structur
four
ctermin
protein
nonstructur
thought
function
viral
replic
hcv
classifi
within
famili
flavivirida
genu
hepaciviru
utr
highli
conserv
region
nt
complex
secondari
structur
contain
intern
ribosom
entri
site
import
translat
long
open
read
frame
utr
contain
short
region
vari
sequenc
length
follow
polypyrimidin
stretch
variabl
length
final
highli
conserv
sequenc
nt
constitut
terminu
genom
function
utr
known
thought
essenti
viral
replic
region
hcv
variabl
region
within
genom
nucleotid
amino
acid
level
two
region
call
hypervari
region
respect
show
extrem
sequenc
variabl
thought
result
select
pressur
antivir
antibodi
also
contain
bind
site
one
put
cell
receptor
coreceptor
hcv
nonstructur
region
contain
zincdepend
autoproteas
cleav
polyprotein
junction
aminotermin
portion
protein
also
serin
proteas
cleav
polyprotein
sever
site
carboxytermin
portion
protein
helicas
activ
import
hcv
replic
protein
cofactor
serin
proteas
region
encod
rnadepend
rna
polymeras
replic
viral
genom
region
link
interferona
ifna
respons
therefor
call
ifnaesensit
determin
region
first
complet
hcv
genom
sequenc
report
choo
et
al
addit
genom
sequenc
isol
differ
part
world
determin
compar
evid
hcv
exist
distinct
genotyp
much
sequenc
divers
whole
viral
genom
much
earli
literatur
genotyp
confus
investig
develop
use
classif
scheme
howev
consensu
nomenclatur
system
develop
system
genotyp
number
use
arab
numer
order
discoveri
close
relat
strain
within
type
design
subtyp
lowercas
letter
complex
genet
variant
found
within
individu
isol
term
quasispeci
quasispeci
result
accumul
mutat
occur
viral
replic
host
genotyp
subtyp
assign
nomenclatur
rule
hcv
recent
updat
major
genotyp
subtyp
hcv
recogn
anoth
provision
subtyp
hcv
strain
belong
differ
genotyp
differ
nucleotid
belong
subtyp
differ
fewer
nucleotid
genom
level
hepat
c
viru
genotyp
found
throughout
world
clear
differ
distribut
hcv
subtyp
respons
infect
north
south
america
europ
japan
unit
state
type
account
approxim
infect
equal
distribut
subtyp
viral
genotyp
correl
diseas
progress
detect
hcv
rna
serum
plasma
na
amplif
method
import
confirm
diagnosi
hcv
distinguish
activ
resolv
infect
assess
virolog
respons
therapi
screen
blood
suppli
test
incorpor
diagnost
algorithm
hepat
c
propos
center
diseas
control
prevent
cdc
american
associ
studi
liver
diseas
nation
academi
clinic
biochemistri
detect
hcv
rna
plasma
serum
earliest
marker
infect
appear
week
infect
week
elev
liver
enzym
appear
antihcv
antibodi
approxim
individu
infect
hcv
chronic
infect
viru
antibodyposit
individu
hcv
rna
test
distinguish
activ
resolv
infect
patient
high
pretest
probabl
infect
posit
serolog
screen
test
result
usual
confirm
test
hcv
rna
rather
recombin
immunoblot
assay
riba
strategi
costeffect
inform
use
riba
confirm
posit
antibodi
screen
test
diagnost
set
howev
discontinu
hcv
riba
manufactur
reactiv
hcv
antibodi
screen
test
follow
fdaapprov
hcv
rna
test
hepat
c
viru
rna
test
also
help
diagnosi
infect
infant
born
hcvinfect
mother
persist
matern
antibodi
immunocompromis
debilit
patient
may
blunt
serolog
respons
hcv
rna
test
also
use
patient
suspect
acut
infect
patient
hepat
identifi
caus
hepat
c
viru
rna
test
reliabl
mean
identifi
patient
activ
hcv
infect
neg
hcv
rna
test
result
serolog
posit
individu
may
indic
infect
resolv
viremia
intermitt
chronic
infect
individu
intermitt
viremia
result
singl
neg
hcv
rna
determin
may
suffici
exclud
activ
infect
index
clinic
suspicion
high
individu
second
specimen
collect
test
use
antihcv
antibodi
test
screen
blood
suppli
dramat
reduc
risk
transfusionassoci
hcv
infect
develop
countri
risk
unit
state
blood
neg
antihcv
antibodi
less
transfus
unit
drive
risk
infect
transfus
even
lower
blood
donor
pool
current
test
presenc
hcv
rna
serolog
screen
test
hcv
window
period
seroneg
antigen
detect
test
yet
avail
blood
product
screen
hcv
rna
test
estim
reduc
detect
window
day
reduc
number
transfus
infecti
unit
per
year
assay
detect
quantif
hcv
core
antigen
serum
recent
commerci
develop
yet
fda
clear
diagnost
use
test
significantli
shorten
serolog
silent
window
period
use
seroconvers
panel
perform
correl
close
rna
detect
test
blood
donor
howev
analyt
sensit
less
rna
test
approxim
iuml
analyt
sensit
core
antigen
test
high
use
monitor
late
event
treatment
antigen
detect
may
repres
costeffect
altern
hcv
rna
test
distinguish
activ
resolv
infect
resourcepoor
set
hepat
c
viral
load
test
use
pretreat
evalu
patient
consid
therapi
viral
load
less
iuml
one
sever
predictor
achiev
sustain
virolog
respons
factor
associ
achiev
sustain
respons
therapi
includ
absenc
cirrhosi
age
younger
year
femal
gender
white
race
viral
genotyp
presenc
two
copi
c
allel
posit
near
gene
ifn
lambda
hepat
c
viral
load
predict
diseas
progress
associ
sever
liver
diseas
sharp
contrast
viral
load
princip
factor
determin
rate
diseas
progress
monitor
hcv
viral
load
untreat
patient
warrant
discourag
recent
standard
therapi
patient
chronic
hcv
infect
pegyl
ifna
combin
ribavirin
administ
either
week
hcv
genotyp
infect
week
hcv
genotyp
infect
sustain
virolog
respons
svr
rate
attain
patient
genotyp
genotyp
infect
svr
defin
absenc
detect
hcv
rna
plasma
serum
determin
test
limit
detect
iuml
less
consid
virolog
cure
first
directact
antivir
daa
treatment
hepat
c
approv
fda
serin
proteas
inhibitor
boceprevir
boc
merck
telaprevir
tvr
vertex
daa
agent
use
combin
pegyl
ifna
ribavirin
tripl
therapi
genotyp
infect
led
approxim
increas
svr
previou
standard
care
therapi
patient
subgroup
tvr
also
activ
genotyp
infect
genotyp
infect
boc
appear
activ
genotyp
infect
howev
neither
drug
use
treat
patient
genotyp
infect
svr
rate
pegyl
ifna
ribavirin
alon
much
higher
import
time
point
responseguid
therapi
week
boc
week
tvr
treatment
three
drug
stop
hcv
rna
greater
iuml
week
detect
week
boc
tripl
therapi
hcv
rna
greater
iuml
week
detect
week
tvr
goal
treatment
svr
defin
detect
hcv
rna
serum
plasma
highli
sensit
assay
limit
detect
iuml
month
end
treatment
patient
achiev
svr
littl
chanc
virolog
relaps
diseas
two
potent
daa
approv
fda
sofosbuvir
gilead
polymeras
inhibitor
simeprevir
johnson
johnson
secondgener
proteas
inhibitor
sofosbuvir
approv
combin
pegyl
ifna
ribavirin
treatment
genotyp
combin
ribavirin
alon
genotyp
simeprevir
approv
fda
treatment
genotyp
infect
combin
pegyl
ifna
ribavirin
patient
genotyp
fail
therapi
firstgener
proteas
inhibitor
monitor
viral
load
treatment
affect
manag
decis
sofosbuvirbas
regimen
treatment
failur
almost
exclus
caus
relaps
howev
given
expens
drug
potenti
risk
viral
resist
inappropri
use
viral
load
test
week
end
treatment
either
week
depend
regimen
seem
prudent
viral
load
determin
week
assess
treatment
respons
possibl
cessat
therapi
patient
treat
simeprevir
pegyl
ifna
ribavirin
discontinu
warrant
patient
unlik
achiev
svr
base
virolog
respons
treatment
hcv
rna
greater
iuml
week
entir
regimen
discontinu
hcv
rna
greater
iuml
week
simeprevir
complet
pegyl
ifna
ribavirin
discontinu
numer
daa
develop
current
clinic
trial
includ
proteas
inhibitor
polymeras
inhibitor
inhibitor
host
cell
protein
requir
hcv
replic
current
recommend
aspect
hcv
treatment
found
http
wwwhcvguidelinesorg
current
three
fdaapprov
hcv
viral
load
assay
avail
commerci
two
assay
use
realtim
pcr
coba
ampliprepcoba
taqman
version
roch
diagnost
realtim
system
abbott
molecular
third
use
branch
dna
signal
amplif
versant
siemen
amplif
method
gene
target
dynam
rang
assay
given
tabl
commerci
avail
assay
calibr
world
health
organ
intern
calibr
standard
report
result
iuml
first
version
coba
taqman
hcv
test
genotyp
bia
particularli
genotyp
sampl
second
version
assay
modifi
enhanc
abil
accur
quantifi
major
hcv
genotyp
develop
first
intern
hcv
rna
standard
accept
manufactur
hcv
rna
assay
calibr
signific
advanc
hcv
rna
quantif
howev
despit
implement
intern
standard
hcv
rna
measur
equival
differ
assay
therefor
patient
ideal
test
assay
cours
treatment
minim
potenti
patient
manag
error
although
number
baselin
factor
predict
respons
treatment
chronic
hepat
c
infect
hcv
genotyp
strong
consist
predictor
achiev
svr
pegyl
ifna
ribavirin
larg
clinic
trial
combin
therapi
pegyl
ifna
ribavirin
patient
infect
genotyp
svr
compar
patient
infect
genotyp
determin
hcv
subtyp
clinic
relev
patient
treat
ifna
ribavirin
differ
treatment
durat
base
viral
load
kinet
recommend
patient
differ
hcv
genotyp
howev
emerg
resist
variant
virolog
breakthrough
common
patient
infect
hcv
subtyp
treat
tvr
tripl
therapi
hcv
subtyp
may
play
role
help
select
treatment
regimen
predict
develop
resist
daa
drug
addit
tripl
therapi
proteas
inhibitor
recommend
patient
infect
genotyp
antiviralresist
mutat
cluster
around
catalyt
site
serin
proteas
emerg
proteas
inhibitor
therapi
associ
failur
relaps
similar
resist
variant
detect
bocand
tvrtreat
patient
suggest
crossresist
occur
proteas
inhibitor
also
antiviralresist
variant
found
patient
treatment
appear
impact
respons
either
proteas
inhibitor
current
role
antivir
resist
genotyp
baselin
treatment
proteas
inhibitor
sever
mutat
proteas
associ
reduc
suscept
simeprevir
one
common
clinic
relev
mutat
substitut
mutat
may
present
baselin
approxim
patient
genotyp
associ
lower
svr
rate
patient
genotyp
mutat
test
recommend
patient
variant
offer
treatment
option
varieti
laboratorydevelop
commerci
assay
use
hcv
genotyp
method
includ
na
sequenc
revers
hybrid
subtypespecif
pcr
dna
fragment
length
polymorph
heteroduplex
mobil
analysi
melt
curv
analysi
serolog
genotyp
current
one
fdaapprov
hcv
genotyp
assay
abbott
realtim
hcv
genotyp
ii
assay
use
realtim
pcr
multipl
hydrolysi
probe
amplifi
differenti
genotyp
subtyp
utr
target
identifi
genotyp
target
subtyp
genotyp
sampl
result
test
shown
good
overal
agreement
direct
sequenc
method
howev
rel
high
rate
indetermin
result
inabl
distinguish
genotyp
subtyp
limit
commerci
avail
revers
hybrid
line
probe
assay
commonli
use
method
genotyp
hcv
among
clinic
laboratori
particip
hcv
proficiencytest
survey
colleg
american
pathologist
revers
hybrid
assay
develop
innogenet
fujirebio
europ
market
versant
hcv
genotyp
assay
siemen
line
probe
assay
lipa
biotinyl
pcr
product
utr
core
region
hcv
genom
hybrid
stringent
condit
oligonucleotid
probe
attach
nitrocellulos
strip
typeand
subtypespecif
probe
interrog
utr
addit
three
probe
interrog
core
region
core
region
probe
ad
provid
better
discrimin
subtyp
genotyp
hybrid
pcr
product
detect
streptavidinealkalin
phosphatas
conjug
pattern
reactiv
line
defin
genotyp
case
subtyp
assay
discrimin
among
genotyp
versant
hcv
genotyp
assay
correctli
identifi
genotyp
distinguish
subtyp
compar
sequenc
may
abl
adequ
identifi
subtyp
mix
genotyp
infect
recogn
unusu
pattern
hybrid
signal
howev
lipa
requir
consider
amount
amplicon
type
assay
may
regularli
fail
viral
load
less
copiesml
sequenc
analysi
amplifi
subgenom
sequenc
definit
way
genotyp
hcv
strain
genotyp
scheme
base
sequenc
variabl
gene
core
provid
enough
resolut
determin
type
subtyp
utr
highli
conserv
discrimin
subtyp
reliabl
genotyp
method
target
highli
variabl
region
higher
failur
rate
primer
mismatch
fail
amplif
reaction
sequenc
reaction
perform
directli
pcr
product
clone
amplicon
mix
infect
multipl
genotyp
may
miss
sequenc
analysi
definit
detect
mix
infect
requir
analysi
larg
number
clone
clone
may
howev
emphas
artifactu
nucleotid
substitut
introduc
dna
polymeras
amplif
select
clone
procedur
gener
practic
clinic
laboratori
standard
direct
sequenc
system
hcv
genotyp
commerci
avail
siemen
trugen
hcv
nc
genotyp
kit
target
utr
nt
employ
proprietari
singletub
chemistri
method
use
amplicon
gener
either
roch
amplicor
hcv
amplicor
hcv
monitor
test
sequenc
templat
column
purif
step
sequenc
chemistri
produc
bidirect
sequenc
softwar
acquir
sequenc
data
pair
forward
revers
sequenc
combin
refer
sequenc
librari
modul
contain
approxim
sequenc
six
major
genotyp
subtyp
hcv
softwar
automat
align
patient
hcv
sequenc
refer
sequenc
librari
report
type
subtyp
closest
isol
determin
trugen
hcv
nc
genotyp
system
reliabl
method
determin
hcv
genotyp
similar
approach
target
conserv
utr
reliabl
distinguish
hcv
subtyp
practic
use
sequenc
analysi
singl
subgenom
region
hcv
genotyp
challeng
descript
natur
occur
intergenotyp
recombin
two
hcv
genotyp
recombin
form
detect
patient
russia
genotyp
vietnam
genotyp
franc
genotyp
well
experiment
infect
chimpanze
genotyp
novel
hcv
genotyp
method
use
solid
phase
electrochem
array
develop
genmark
diagnost
method
use
sequenc
specif
captur
pcr
amplicon
hcv
utr
surfacebound
oligonucleotid
captur
probe
form
within
preassembl
monolay
electrochem
detect
use
ferrocenelabel
oligonucleotid
signal
probe
high
genotyp
concord
genmark
lipa
hcv
test
observ
howev
minor
discrep
genotyp
subtyp
identif
two
test
due
differ
region
hcv
genom
interrog
widespread
use
test
clear
fda
hcv
genotyp
place
increas
burden
clinic
laboratori
verifi
perform
characterist
test
clinic
use
valid
hcv
genotyp
test
laboratori
take
advantag
publish
evalu
commerci
avail
genotyp
panel
streamlin
verif
process
colleg
american
pathologist
wellestablish
profici
test
program
laboratori
perform
test
detect
quantif
character
hcv
rna
survey
shown
steadi
improv
perform
laboratori
time
probabl
reflect
progress
avail
technolog
laboratori
practic
hepat
c
viru
approxim
million
peopl
live
activ
hcv
infect
unit
state
hcv
common
caus
chronic
liver
diseas
hcv
viral
load
predict
progress
sever
liver
diseas
import
distinguish
activ
resolv
infect
wide
accept
marker
respons
therapi
although
seven
major
hcv
genotyp
numer
subtyp
differ
geograph
distribut
genotyp
infect
predomin
much
develop
world
histor
difficult
success
treat
use
ifna
ribavirin
treatment
respons
rate
genotyp
infect
dramat
improv
fda
clearanc
daa
agent
target
hcv
proteas
polymeras
current
role
hcv
resist
genotyp
guid
therapi
may
chang
number
daa
agent
increas
hepat
b
viru
hbv
small
envelop
dna
viru
belong
famili
hepadnavirida
caus
transient
persist
chronic
infect
liver
famili
divid
two
genera
orthohepadnaviru
avihepadnaviru
infect
mammal
bird
natur
host
respect
possess
narrow
host
rang
determin
initi
step
viral
attach
entri
approxim
billion
peopl
serolog
evid
hepat
b
approxim
million
peopl
chronic
infect
depend
viral
host
factor
outcom
infect
hbv
rang
clearanc
mild
sever
chronic
hepat
chb
develop
cirrhosi
hepatocellular
carcinoma
hcc
evolut
increasingli
sensit
method
hbv
dna
detect
accur
quantif
creat
import
role
molecular
test
routin
patient
care
improv
method
sequenc
singl
mutat
detect
led
test
document
mutat
chang
viral
genom
current
na
test
play
critic
role
overal
care
hbvinfect
patient
hbv
genom
relax
circular
partial
doublestrand
dna
molecul
four
partial
overlap
open
read
frame
encod
viral
envelop
pre
nucleocapsid
precor
core
polymeras
x
protein
bind
hepatocyt
virion
taken
cell
endocytosi
uncoat
partial
doublestrand
dna
genom
convert
coval
close
circular
dna
cccdna
cell
nucleu
cccdna
use
templat
transcript
pregenom
rna
pgrna
messeng
rna
cell
nucleu
pgrna
move
host
cell
cytoplasm
serv
templat
translat
hbv
rt
well
core
protein
cellular
translat
protein
concurr
hbv
rt
revers
transcrib
pgrna
new
circular
dna
molecul
earli
replic
cycl
newli
synthes
genom
circul
back
nucleu
maintain
increas
pool
cccdna
although
hbv
dna
viru
replic
rt
lack
proofread
activ
result
prone
error
overlap
open
read
frame
genom
limit
type
mutat
toler
howev
variat
hbv
sequenc
detect
almost
region
genom
consequ
hbv
exist
quasispeci
differ
patient
may
infect
differ
strain
genotyp
seven
phylogenet
genotyp
h
hbv
identifi
distinct
geograph
distribut
genotyp
defin
intergroup
diverg
greater
complet
genom
nucleotid
sequenc
known
genotyp
found
unit
state
preval
b
c
e
g
respect
recent
data
suggest
hbv
genotyp
play
import
role
progress
hbvrelat
liver
diseas
well
respons
ifna
pegyl
ifna
howev
hbv
genotyp
necessari
routin
clinic
practic
serolog
assay
high
sensit
specif
reproduc
develop
detect
hbv
antigen
respect
antibodi
complic
system
serolog
marker
use
diagnosi
hbv
infect
defin
phase
infect
degre
infect
prognosi
patient
immun
statu
presenc
hbv
dna
serum
marker
viral
replic
liver
replac
hepat
b
e
antigen
hbeag
sensit
marker
viral
replic
hbeag
extracellular
form
hepat
b
core
protein
molecular
assay
quantifi
blood
hbv
dna
use
initi
evalu
hbv
infect
monitor
patient
chronic
infect
assess
efficaci
antivir
treatment
addit
us
blood
donor
routin
screen
hbv
dna
qualit
test
detect
donor
earli
stage
infect
antivir
resist
mutat
detect
molecular
method
identifi
known
mutat
associ
drug
resist
initi
evalu
patient
found
hepat
b
surfac
antigen
hbsag
serum
includ
routin
liver
test
varieti
virolog
test
includ
hbv
dna
test
chronic
hbv
infect
diseas
variabl
cours
establish
baselin
laboratori
valu
time
diagnosi
import
clinic
track
diseas
progress
time
evalu
candid
liver
biopsi
monitor
diseas
activ
chronic
hbvinfect
patient
best
done
measur
aminotransferas
alt
regular
interv
hbeagposit
patient
howev
serial
hbv
dna
test
recommend
hbeagneg
patient
determin
serum
hbv
dna
viral
load
import
pretreat
evalu
monitor
therapeut
respons
patient
chronic
infect
current
therapi
chronic
hbv
infect
erad
viru
limit
longterm
efficaci
decis
treat
base
alt
elev
presenc
hbeag
hbv
dna
viral
load
greater
iuml
presenc
moder
diseas
activ
fibrosi
liver
biopsi
virolog
test
exclud
concurr
infect
hepat
viru
hdv
hcv
hiv
treatment
goal
chronic
hepat
b
achiev
sustain
suppress
hbv
replic
prevent
progress
liver
diseas
paramet
use
indic
treatment
respons
includ
normal
serum
alt
decreas
serum
hbv
dna
loss
hbeag
without
detect
antihbeag
current
eight
fdaapprov
therapi
chronic
hbv
infect
ifna
pegyl
four
nucleosid
analog
lamivudin
telbivudin
entecavir
emtricitabin
two
nucleotid
analog
adefovir
tenofovir
sever
factor
predict
favor
respons
ifn
treatment
import
high
alt
low
serum
hbv
dna
viral
load
indirect
marker
immun
clearanc
therapi
usual
erad
viru
coval
close
circular
form
hbv
genom
difficult
elimin
liver
exist
extrahepat
reservoir
hbv
endpoint
treatment
tradit
clearanc
hbeag
develop
antihb
antibodi
undetect
serum
hbv
dna
use
insensit
hybrid
assay
detect
limit
approxim
genom
copiesml
achiev
endpoint
usual
accompani
resolut
liver
diseas
evidenc
normal
alt
decreas
inflamm
liver
biopsi
respons
usual
sustain
longterm
followup
nevertheless
respond
continu
detect
hbv
dna
sensit
na
amplif
test
use
respons
antivir
therapi
categor
biochem
virolog
histolog
therapi
sustain
therapi
sever
variat
nucleotid
sequenc
hbv
import
clinic
consequ
import
mutat
gene
encod
hbsag
glycinetoarginin
substitut
codon
conserv
determin
caus
decreas
affin
hbsag
antihb
antibodi
hbv
mutat
found
children
hbsagposit
mother
develop
hbv
infect
despit
vaccin
adequ
antihb
antibodi
respons
vaccin
well
liver
transplant
recipi
recurr
infect
despit
administr
hbv
immun
globulin
immun
escap
mutant
rais
concern
vaccin
efficaci
serolog
silent
infect
mutat
report
mani
countri
respons
vaccin
failur
although
diminish
bind
antihb
antibodi
vast
major
mutant
readili
detect
current
gener
hbsag
test
thu
initi
concern
widespread
use
hbv
immun
globulin
vaccin
would
result
hbv
mutant
would
escap
detect
hbsag
test
unfound
mutat
basal
core
promot
precor
gene
affect
synthesi
hbeag
commonli
aris
immun
pressur
common
basal
core
promot
mutat
dual
chang
nt
g
nt
diminish
amount
mrna
henc
hbeag
secret
predomin
precor
mutat
g
chang
nt
lead
prematur
termin
precor
protein
codon
thu
prevent
product
hbeag
mutat
infrequ
north
america
western
europ
geograph
widespread
geograph
variabl
frequenc
relat
predomin
genotyp
geograph
region
mutat
found
genotyp
b
c
e
mutat
first
report
patient
chronic
activ
hepat
fulmin
hepat
howev
mutat
also
present
asymptomat
carrier
virus
mutat
replic
effici
wildtyp
hbv
thu
pathophysiolog
signific
mutat
unclear
howev
clinic
pictur
persist
hbv
replic
activ
liver
diseas
hbeagneg
patient
appear
increasingli
preval
region
viru
may
preval
wildtyp
viru
therapi
chronic
hepat
b
requir
long
cours
treatment
nucleosid
nucleotid
analog
major
concern
longterm
therapi
develop
antivir
resist
mutat
one
domain
gene
encod
hbv
polymeras
rate
resist
mutant
select
relat
pretreat
serum
hbv
dna
viral
load
rapid
viral
suppress
durat
treatment
prior
antivir
exposur
incid
genotyp
resist
also
vari
sensit
method
use
detect
resist
mutat
patient
popul
test
typic
patient
experi
virolog
breakthrough
defin
increas
serum
hbv
dna
greater
log
nadir
achiev
virolog
respons
continu
treatment
hbv
resist
genotyp
perform
standard
nomenclatur
hbv
antivir
resist
mutat
polymeras
shown
tabl
hbv
mutat
associ
resist
ifna
pegyl
number
commerci
avail
test
quantif
hbv
dna
serum
plasma
two
test
unit
statesin
vitro
diagnost
usivd
regulatori
statu
testsdth
coba
ampliprepcoba
taqman
roch
realtim
abbott
hbv
testsd
use
realtim
pcr
see
tabl
other
produc
cepheid
qiagen
siemen
ce
mean
european
conform
mark
ruo
kit
asr
unit
state
intern
hbv
standard
first
creat
respons
recogn
need
standard
hbv
dna
quantif
assay
howev
despit
avail
hbv
dna
standard
variou
quantit
assay
usual
differ
convers
factor
copi
iuml
may
reflect
differ
amplif
detect
chemistri
laboratori
report
hbv
viral
load
test
result
iuml
log
transform
arithmet
valu
hbv
includ
hepat
viral
load
profici
test
survey
avail
colleg
american
pathologist
two
hbv
genotyp
system
commerci
avail
ruo
kit
innogenet
fujirebio
europ
offer
three
differ
line
probe
assay
hbv
phylogenet
genotyp
detect
precor
mutat
detect
relev
lamivudin
emtricitabin
telbivudin
adefovir
entecavir
resist
mutat
well
known
compensatori
mutat
assay
use
pcr
amplifi
portion
relev
gene
produc
biotinyl
product
pcr
product
denatur
hybrid
seri
inform
probe
immobil
nitrocellulos
strip
hybrid
visual
strip
addit
streptavidinealkalin
phosphatas
colorimetr
substrat
mutat
identifi
color
pattern
pcr
product
hybrid
probe
line
probe
assay
typic
better
sensit
detect
sequenc
variant
direct
sanger
sequenc
trugen
hbv
genotyp
test
siemen
use
two
fluoresc
label
dna
primer
pcr
amplifi
portion
hbsag
gene
overlap
polymeras
gene
bidirect
sequenc
amplicon
softwar
modul
includ
sequenc
databas
identifi
phylogenet
genotyp
h
well
mutat
associ
resist
nucleosid
nucleotid
analog
drug
sequenc
ladder
resolv
polyacrylamid
slab
gel
total
analysi
time
approxim
hour
includ
time
requir
dna
extract
purif
standard
nomenclatur
report
hbv
antivir
resist
mutat
shown
tabl
use
resist
genotyp
perform
inabl
genotyp
assay
detect
minor
popul
circul
hbv
signific
technic
issu
gener
direct
sequenc
limit
resolut
popul
viral
popul
cytomegaloviru
cmv
member
herpesvirida
famili
envelop
doublestrand
dna
viru
larg
genom
approxim
dna
homolog
among
differ
strain
cmv
usual
caus
asymptomat
minor
infect
immunocompet
individu
remain
import
pathogen
immunocompromis
individu
includ
person
aid
transplant
recipi
immunemodul
drug
primari
infect
usual
asymptomat
immunocompet
person
although
small
percentag
individu
cmv
infect
may
develop
syndrom
similar
mononucleosi
primari
infect
lifelong
latent
infect
establish
caus
clinic
symptom
howev
infect
individu
becom
immunocompromis
viru
reactiv
lead
wide
varieti
clinic
syndrom
sever
cmv
infect
seen
patient
acquir
primari
infect
immunocompromis
person
aid
cmv
diseas
rare
occur
cell
count
cellsmm
common
clinic
present
retin
esophag
coliti
transplant
recipi
occurr
sever
cmv
diseas
relat
cmv
serostatu
organ
donor
recipi
type
organ
transplant
overal
degre
immunosuppress
exampl
cmv
diseas
tend
sever
lung
transplant
recipi
renal
transplant
recipi
type
solid
organ
recipi
sever
diseas
occur
cmvseroneg
recipi
receiv
organ
cmvseroposit
donor
primari
cmv
infect
occur
person
immunosuppress
contrast
cmvseroposit
recipi
hematopoiet
stem
cell
cmvseroneg
donor
highest
risk
cmv
diseas
hematopoiet
stem
cell
transplant
hsct
cmv
diseas
also
occur
seroposit
individu
whether
receiv
organ
seroposit
seroneg
donor
clinic
find
associ
cmv
diseas
transplant
recipi
divers
includ
interstiti
pneumon
esophag
coliti
fever
leukopenia
less
commonli
retin
enceph
diagnosi
cmv
diseas
repres
challeng
latent
infect
common
immunocompromis
individu
asymptomat
clinic
insignific
lowlevel
persist
infect
must
distinguish
clinic
import
activ
cmv
diseas
distinct
challeng
sensit
molecular
assay
use
detect
small
amount
cmv
dna
clinic
specimen
tradit
diagnosi
cmv
diseas
reli
detect
cmv
clinic
specimen
use
cell
cultur
techniqu
human
diploid
fibroblast
although
consid
gold
standard
convent
cultur
method
labor
intens
turnaround
time
tat
week
addit
assay
lack
adequ
sensit
detect
cmv
blood
specimen
rapid
shellvial
cultur
method
provid
result
day
use
detect
cmv
tissu
respiratori
urin
specimen
howev
method
may
also
fail
detect
cmv
blood
mani
year
laboratori
reli
cmv
antigenemia
assay
detect
matrix
protein
circul
polymorphonuclear
white
blood
cell
semiquantit
assay
rapid
cultur
number
cmv
antigenposit
cell
correl
likelihood
cmv
diseas
assay
labor
intens
subject
nonstandard
consequ
longer
done
clinic
laboratori
consid
limit
cultur
great
interest
use
na
test
detect
quantif
cmv
dna
blood
specimen
clinic
use
cmv
molecular
assay
divers
includ
initi
preemptiv
therapi
diagnosi
activ
cmv
diseas
monitor
respons
therapi
preemptiv
therapi
identifi
group
individu
higher
risk
develop
cmv
diseas
exampl
member
group
would
test
presenc
cmv
dna
blood
plasma
test
posit
would
treat
therapi
administ
develop
symptom
attempt
prevent
onset
activ
diseas
contrast
prophylact
therapi
patient
group
treat
without
stratif
risk
thu
involv
treatment
greater
number
patient
preemptiv
therapi
becom
standard
care
manag
hsct
recipi
molecular
assay
use
diagnos
activ
cmv
diseas
cmv
dna
concentr
higher
patient
activ
cmv
diseas
asymptomat
infect
quantit
pcr
plasma
whole
blood
commonli
use
diagnos
cmv
diseas
monitor
respons
therapi
recent
fdaapprov
cmv
viral
load
test
laboratori
use
varieti
differ
laboratorydevelop
test
detect
quantif
cmv
dna
therefor
threshold
viral
load
cutoff
diagnosi
made
preemptiv
therapi
begun
vari
among
institut
transplant
popul
univers
viral
load
cutoff
defin
cmv
diseas
establish
health
care
provid
reli
trend
viral
load
valu
time
rather
valu
obtain
singl
point
time
diagnosi
patient
manag
activ
cmv
diseas
diagnos
molecular
assay
use
monitor
respons
therapi
viral
load
valu
decreas
rapidli
appropri
antivir
therapi
begun
cmv
dna
clear
plasma
within
sever
week
initi
therapi
failur
viral
load
decreas
promptli
rais
concern
possibl
treatment
failur
persist
elev
concentr
cmv
dna
therapi
indic
therapeut
resist
molecular
assay
also
identifi
patient
risk
relaps
cmv
infect
solid
organ
transplant
recipi
patient
detect
viral
load
complet
day
ganciclovir
therapi
cmv
infect
increas
risk
relaps
rate
declin
cmv
dna
initi
therapi
also
use
predict
risk
relaps
cmv
infect
cytomegaloviru
dna
concentr
also
use
assess
risk
develop
cmv
diseas
person
aid
detect
cmv
dna
plasma
associ
increas
risk
develop
cmv
diseas
increas
risk
death
addit
log
increas
viral
load
ie
increas
concentr
associ
threefold
increas
risk
develop
cmv
diseas
current
two
fdaapprov
cmv
viral
load
assay
see
tabl
capctm
cmv
test
roch
artu
cmv
rgq
mdx
qiagen
base
realtim
pcr
calibr
cmv
standard
consequ
report
result
intern
unit
per
millilit
roch
test
amplifi
portion
gene
qiagen
test
amplifi
portion
mie
gene
assay
similar
lower
limit
quantif
qiagen
assay
greater
dynam
rang
despit
avail
intern
standard
fdaapprov
assay
still
consider
interlaboratori
variabl
result
cmv
profici
test
survey
epsteinbarr
viru
epsteinbarr
viru
ebv
doublestrand
dna
viru
belong
herpesvirida
famili
seropreval
ebv
greater
among
adult
older
age
year
primari
infect
follow
lifelong
latenc
reactiv
infect
immunocompromis
host
transplant
recipi
ebv
infect
may
caus
malais
fever
headach
sore
throat
also
associ
posttransplant
lymphoprolif
diseas
ptld
signific
caus
morbid
mortal
ptld
spectrum
lymphocyt
prolifer
rang
benign
lymphocyt
hyperplasia
potenti
fatal
malign
lymphoma
process
often
multicentr
may
involv
central
nervou
system
cn
eye
gastrointestin
gi
tract
bleed
perfor
liver
spleen
lymph
node
lung
allograft
oropharynx
organ
clinic
present
vari
includ
limit
adenopathi
fever
includ
fever
unknown
origin
abdomin
pain
anorexia
jaundic
bowel
perfor
gi
bleed
renal
dysfunct
liver
dysfunct
pneumothorax
pulmonari
infiltr
nodul
weight
loss
pathogenesi
ptld
involv
exponenti
prolifer
b
cell
result
uncontrol
ebv
infect
risk
factor
includ
donor
recipi
serolog
mismatch
eg
donor
positiverecipi
neg
high
degre
immunosuppress
particularli
use
antilymphocyt
therapi
reject
high
ebv
viral
load
case
ptld
occur
first
year
transplant
cumul
incid
rang
hsct
liver
transplant
recipi
intestin
multiorgan
transplant
recipi
treatment
ebvrel
lymphoprolif
diseas
challeng
lymphoprolif
diseas
establish
antivir
treatment
effect
immunosuppress
must
reduc
murin
human
chimer
monoclon
antibodi
rituximab
help
case
patient
requir
chemotherapi
radiat
therapi
adopt
immunotherapi
use
donorderiv
clone
ebvspecif
cytotox
cell
may
use
prophylaxi
treatment
lymphoprolif
diseas
allogen
hsct
solid
organ
transplant
recipi
increas
ebv
viral
load
may
detect
patient
develop
ebvassoci
ptld
viral
load
typic
decreas
effect
therapi
wherea
high
ebv
dna
viral
load
strong
predictor
develop
ptld
lowlevel
ebv
viral
load
occur
rel
frequent
may
resolv
without
intervent
complic
matter
pediatr
liver
heart
transplant
recipi
may
exhibit
chronic
high
ebv
viral
load
avail
assay
lack
standard
optim
assay
techniqu
sampl
type
ie
whole
blood
lymphocyt
plasma
sampl
schedul
defin
nevertheless
ebv
viral
load
assay
gener
sensit
specif
precis
linear
across
wide
dynam
rang
rapid
reason
inexpens
overal
use
patient
care
although
defin
trigger
point
predict
ptld
persist
detect
concentr
ebv
dna
pcr
cutoff
vari
program
typic
result
thorough
evalu
ptld
eg
comput
tomographi
chest
abdomen
pelvi
epsteinbarr
viru
viral
load
test
also
indic
transplant
recipi
present
lymphadenopathi
fever
sign
symptom
suggest
lymphoprolif
diseas
high
ebv
load
trigger
search
mass
lesion
organ
dysfunct
pinpoint
potenti
site
diseas
biopsi
current
fdaapprov
ebv
viral
load
test
avail
wide
varieti
commerci
avail
primer
probe
differ
gene
target
use
laboratori
develop
test
ldt
deploy
clinic
laboratori
consensu
best
target
gene
specimen
type
whole
blood
white
blood
cell
plasma
howev
first
intern
standard
ebv
dna
develop
address
variat
assay
result
attribut
calibr
http
wwwnibscorgdocu
definit
diagnosi
ptld
requir
biopsi
tissu
patient
ebvassoci
lymphoprolif
diseas
may
show
monoclon
oligoclon
polyclon
lesion
diagnosi
ebvassoci
lymphoprolif
diseas
requir
demonstr
ebv
dna
rna
protein
biopsi
tissu
situ
hybrid
target
gold
standard
assay
determin
whether
lymphoprolif
process
ebv
relat
commerci
system
eber
situ
hybrid
avail
ventana
leica
dako
invitrogen
biogenex
bk
viru
bkv
member
famili
polyomavirida
also
includ
jc
viru
jcv
simian
viru
envelop
doublestrand
dna
viru
share
approxim
sequenc
homolog
jcv
seropreval
reach
nearli
earli
childhood
gener
asymptomat
primari
infect
although
fever
nonspecif
upper
respiratori
tract
symptom
may
occur
seropreval
declin
adulthood
primari
infect
viru
remain
latent
mani
site
notabl
epithelium
urinari
tract
lymphoid
cell
immunosuppress
state
allow
reactiv
replic
viru
replic
bkv
immunocompromis
host
may
asymptomat
caus
organ
dysfunct
affect
kidney
bladder
uret
bkv
diseas
urinari
system
manifest
hemorrhag
nonhemorrhag
cystiti
ureter
stenosi
bone
marrow
solid
organ
transplant
recipi
also
caus
polyomavirusassoci
nephropathi
pvan
renal
transplant
recipi
hemorrhag
cystiti
hc
caus
morbid
occasion
mortal
patient
undergo
bone
marrow
transplant
manifest
rang
microscop
hematuria
sever
bladder
hemorrhag
lead
clot
retent
renal
failur
incid
vari
bone
marrow
transplant
recipi
although
mild
hc
usual
resolv
support
care
sever
hc
may
requir
bladder
irrig
cystoscopi
cauter
bkv
observ
earli
studi
associ
develop
hc
bone
marrow
transplant
howev
later
studi
use
sensit
pcr
assay
show
bkv
dna
could
detect
blood
urin
patient
without
hc
recent
quantit
assay
bkv
dna
urin
demonstr
patient
hc
higher
peak
bk
viruria
larger
total
amount
bkv
excret
bone
marrow
transplant
compar
asymptomat
patient
although
bkv
first
isol
urin
renal
transplant
recipi
associ
nephropathi
presenc
bkv
renal
transplant
recipi
report
bkv
replic
renal
allograft
lead
progress
graft
dysfunct
potenti
graft
failur
although
recognit
pvan
renal
transplant
recipi
coincid
use
newer
immunosuppress
drug
tacrolimu
sirolimu
mycophenol
mofetil
risk
factor
develop
pvan
elucid
preval
pvan
rang
kidney
transplant
recipi
loss
allograft
function
one
third
half
case
diseas
appear
result
reactiv
bkv
infect
donor
allograft
sign
symptom
pvan
mild
nonspecif
often
gradual
increas
serum
creatinin
week
allograft
lose
function
definit
diagnosi
pvan
obtain
histopatholog
biopsi
kidney
characterist
pvan
pattern
includ
viral
cytopath
chang
epitheli
cell
interstiti
inflamm
fibrosi
howev
chang
pathognomon
pvan
center
use
immunohistochem
stain
antibodi
specif
polyomaviru
protein
situ
hybrid
confirm
diagnosi
focal
natur
nephropathi
possibl
sampl
error
neg
biopsi
rule
pvan
biopsi
kidney
invas
procedur
impract
serial
monitor
earli
diagnosi
clinic
manag
patient
pvan
less
invas
diagnost
method
pvan
also
assess
urin
cytolog
may
reveal
renal
epitheli
cell
intranuclear
viral
inclus
bodi
term
decoy
cell
sensit
specif
decoy
cell
diagnos
pvan
respect
posit
predict
valu
vari
quantif
bkv
dna
mrna
urin
na
amplif
method
propos
method
monitor
chang
bkv
replic
howev
physiolog
chang
urin
constitu
use
differ
urin
fraction
may
give
rise
consider
variat
viral
load
valu
may
complic
identif
diagnost
threshold
quantit
crosssect
longitudin
studi
pcr
method
detect
quantit
bk
viremia
emerg
clinic
use
tool
diagnosi
manag
pvan
viremia
preced
develop
nephropathi
almost
case
expert
interdisciplinari
panel
recommend
use
either
urin
cytolog
na
amplif
test
screen
renal
transplant
recipi
bk
viruria
everi
month
year
posttranspl
allograft
dysfunct
occur
biopsi
perform
patient
posit
screen
test
result
adjunct
quantit
na
amplif
test
perform
use
urin
plasma
patient
urin
dna
load
copiesml
plasma
dna
load
copiesml
persist
week
presumpt
pvan
renal
biopsi
perform
confirm
diagnosi
reduc
intens
mainten
immunosuppress
primari
intervent
patient
pvan
effect
antivir
agent
bkv
avail
lowdos
cidofovir
use
treatment
case
amen
refractori
decreas
mainten
immunosuppress
viral
load
urin
plasma
monitor
everi
week
gaug
effect
intervent
current
realtim
pcr
method
choic
bkv
dna
quantif
simplic
wide
dynam
rang
log
viru
copiesml
high
concentr
plasma
uncommon
exceed
copiesml
although
bk
viral
load
test
becom
standard
care
diagnosi
monitor
patient
pvan
neither
consensu
design
pcr
assay
recogn
standard
refer
materi
consequ
assay
develop
differ
laboratori
may
give
markedli
differ
result
requir
individu
laboratori
establish
verifi
clinic
threshold
valu
polymeras
chain
reaction
assay
design
complic
high
degre
homolog
genom
differ
human
polyomavirus
gene
target
bkvspecif
assay
includ
code
sequenc
larg
antigen
agnoprotein
sequenc
suffici
variabl
among
human
polyomavirus
bkv
classifi
seven
subtyp
base
phylogenet
analysi
fullgenom
sequenc
subtyp
ia
ic
ii
iii
iv
v
vi
hoffman
et
al
compar
seven
taqman
realtim
pcr
primereprob
set
conjunct
two
differ
refer
standard
quantifi
bkv
dna
urin
sampl
observ
substanti
disagr
among
assay
attribut
featur
primer
probe
design
choic
refer
materi
signific
sourc
error
primer
probe
mismatch
caus
bkv
subtyp
polymorph
primarili
among
subtyp
iii
iv
isol
howev
found
less
subtyp
bia
among
seven
assay
common
subtyp
ia
v
vi
assay
provid
reliabl
measur
subtyp
includ
mixtur
primer
probe
target
larg
antigen
sequenc
test
chlamydia
trachomati
ct
neisseria
gonorrhoea
ng
discuss
togeth
sever
avail
na
amplif
test
naat
pathogen
multiplex
assay
although
ct
ng
caus
varieti
clinic
infect
focu
genit
infect
detect
ct
challeng
import
public
health
issu
ct
major
caus
sexual
transmit
infect
sti
estim
million
case
occur
annual
among
sexual
activ
adolesc
young
adult
unit
state
half
infect
asymptomat
even
symptomat
diagnosi
miss
manifest
protean
men
ct
infect
may
present
urethr
epididym
prostat
proctiti
cervic
endometr
urethr
women
infect
women
progress
pelvic
inflammatori
diseas
pid
untreat
relat
complic
includ
chronic
pelvic
pain
ectop
pregnanc
infertil
unit
state
ct
infect
like
caus
secondari
infertil
women
pregnant
women
addit
risk
transmit
infect
newborn
labor
deliveri
lead
pneumonia
conjunct
newborn
n
gonorrhoea
infect
may
present
variou
way
clinic
present
overlap
ct
men
may
acut
urethr
discharg
epididym
prostat
urethr
strictur
women
ng
infect
produc
cervic
left
untreat
lead
pid
abscess
salping
tradit
method
diagnosi
ct
infect
includ
cell
cultur
antigen
detect
immunofluoresc
enzym
immunoassay
eia
nonamplifi
na
probe
tradit
method
replac
laboratori
amplifi
na
test
provid
greater
sensit
detect
ct
genit
specimen
ng
tradit
diagnos
base
cultur
method
reli
select
cultur
media
na
test
offer
signific
improv
sensit
compar
cultur
cultur
perform
appropri
condit
ng
highli
suscept
extrem
temperatur
desicc
lead
decreas
sensit
detect
cultur
particularli
specimen
transport
requir
cultur
na
test
ng
offer
sensit
reliabl
altern
cultur
sinc
easier
maintain
integr
target
na
maintain
organ
viabil
addit
high
diagnost
analyt
sensit
specif
na
test
offer
sever
advantag
convent
cultur
antigen
detect
method
diagnosi
ct
ng
test
pathogen
done
singl
specimen
multiplex
assay
test
perform
singl
reaction
unlik
infecti
organ
dna
rna
ng
ct
quit
stabl
commerci
transport
devic
thu
account
increas
diagnost
sensit
assay
compar
cultur
stabil
na
avoid
necess
immedi
transport
laboratori
specimen
may
store
refriger
room
temperatur
transport
transport
storag
requir
vari
among
test
import
refer
packag
insert
specif
detail
addit
advantag
na
test
use
urin
specimen
women
allow
test
done
without
need
pelvic
examin
men
urin
offer
conveni
diagnost
sensit
altern
collect
urethr
swab
increas
likelihood
asymptomat
men
agre
test
naat
detect
ct
ng
clinic
specimen
use
varieti
specimen
includ
cervic
vagin
swab
urethr
swab
urin
asymptomat
symptomat
individu
assay
clear
fda
use
unit
state
condit
age
rang
current
assay
fdaclear
oropharyng
rectal
conjunctiv
specimen
howev
mani
test
assess
diagnos
infect
multipl
extragenit
anatom
site
men
women
children
current
cdc
guidelin
laboratorybas
detect
ct
ng
recommend
naat
oropharyng
rectal
specimen
use
evalu
case
adult
pediatr
sexual
abus
howev
use
test
outsid
fdaapprov
indic
requir
laboratori
establish
specif
perform
characterist
accord
clinic
laboratori
improv
amend
clia
regul
perform
characterist
vari
among
assay
detail
avail
packag
insert
gener
comment
made
diagnost
sensit
test
vari
accord
specimen
type
whether
patient
asymptomat
symptomat
interpret
result
na
test
ct
challeng
mani
studi
shown
assay
diagnost
sensit
cultur
previous
use
gold
standard
clinic
trial
men
diagnost
sensit
test
urin
specimen
nearli
equival
test
urethr
swab
limit
volum
ml
firstpass
urin
prefer
larger
volum
lead
decreas
concentr
organ
sampl
thu
reduc
diagnost
sensit
proper
specimen
collect
male
urethr
swab
urin
specimen
sensit
nearli
detect
ng
ct
infect
women
vagin
cervic
swab
specimen
provid
highest
sensit
detect
ng
ct
infect
mani
studi
show
sensit
vagin
swab
prefer
easier
collect
urin
specimen
use
gener
result
lower
diagnost
sensit
cervic
swab
altern
urin
test
women
use
selfcollect
vagin
swab
shown
studi
diagnost
sensit
equal
obtain
cervic
swab
sever
commerci
test
clear
use
vagin
swab
decis
regard
select
specif
amplif
test
detect
ct
ng
base
sole
cost
reagent
key
factor
consid
includ
test
perform
characterist
diagnost
sensit
specif
applic
urin
swab
specimen
symptomat
asymptomat
individu
ideal
test
includ
intern
control
particularli
crude
lysat
use
assay
factor
consid
degre
autom
eas
use
work
flow
issu
space
equip
need
histor
sever
ng
assay
reduc
specif
due
presenc
gene
target
nongonococc
neisseria
spp
current
probetec
test
bectondickinson
produc
falseposit
result
commens
speci
includ
neisseria
lactamica
neisseria
subflava
neisseria
cinerea
tabl
none
naat
ct
known
biolog
falseposit
result
presenc
gene
target
organ
sourc
falseposit
result
includ
carryov
contamin
amplifi
product
crosscontamin
specimen
collect
transport
process
concern
issu
led
consider
supplement
test
ctor
ngposit
specimen
use
altern
target
test
falseposit
result
psychosoci
medicoleg
ramif
howev
current
recommend
advis
confirm
posit
naat
unless
otherwis
indic
packag
insert
test
known
crossreact
commens
neisseria
spp
falseposit
result
lowpreval
popul
significantli
reduc
predict
valu
posit
result
dna
persist
urin
sampl
week
complet
therapi
test
cure
use
na
test
discourag
must
done
test
delay
least
week
therapi
complet
allow
time
clearanc
dna
pathogen
falseneg
result
inhibit
amplif
consider
ng
ct
test
occur
cervic
swab
urin
specimen
inhibit
rate
may
vari
consider
depend
amplif
na
extract
method
use
test
use
crude
lysat
eg
probetec
inhibit
rate
tend
higher
seen
aptima
combo
test
use
target
captur
method
purifi
na
assay
test
crude
lysat
use
amplifi
anoth
na
sequenc
intern
control
amplif
control
assess
inhibit
amplif
result
report
neg
ng
ct
amplif
intern
control
document
conserv
cryptic
plasmid
found
strain
ct
contain
gene
target
sever
naat
howev
new
variant
nv
strain
ct
emerg
sweden
delet
cryptic
plasmid
contain
target
sever
ct
test
delet
led
falseneg
result
test
target
cryptic
plasmid
current
version
naat
ct
modifi
detect
nv
strain
ct
obvious
test
target
sequenc
contain
cryptic
plasmid
detect
rare
strain
ct
lack
plasmid
perform
ct
ng
test
liquid
cytolog
media
matter
interest
singl
specimen
use
cervic
cancer
screen
papanicola
pap
human
papillomaviru
hpv
test
ct
ng
test
latter
two
test
perform
liquid
specimen
remain
complet
pap
hpv
test
howev
sever
drawback
approach
must
consid
instrument
use
prepar
pap
test
design
control
crosscontamin
process
may
lead
falseposit
result
ct
ng
test
perform
pap
smear
hpv
test
complet
delay
diagnosi
treatment
ct
ng
infect
moreov
remain
specimen
may
inadequ
complet
ct
ng
test
thu
requir
patient
make
return
visit
collect
addit
sampl
remov
aliquot
ct
ng
test
pap
test
perform
prealiquot
may
help
overcom
issu
provid
adequ
volum
sampl
remain
pap
hpv
test
approach
complet
remov
risk
crosscontamin
specimen
must
handl
manner
consist
procedur
use
molecular
laboratori
addit
naat
ct
ng
fda
approv
use
liquid
cytolog
media
trichomoniasi
sti
caus
protozoan
trichomona
vaginali
although
vaginali
infect
report
diseas
unit
state
preval
nonvir
sti
unit
state
vaginali
infect
may
present
vagin
women
urethr
men
howev
frequent
asymptomat
infect
vaginali
may
also
caus
addit
advers
health
outcom
includ
pid
women
well
infertil
increas
incid
hiv
transmiss
women
men
current
recommend
vaginali
diagnosi
treatment
found
http
avail
diagnost
test
rang
simpl
microscopi
naat
microscop
examin
vagin
fluid
urethr
discharg
vaginali
wet
mount
clinic
commonli
use
test
low
sensit
experienc
observ
highli
specif
cultur
long
consid
gold
standard
test
requir
special
medium
day
complet
howev
recent
studi
indic
sensit
cultur
may
low
pap
test
suitabl
routin
screen
diagnosi
low
sensit
singl
rapid
antigen
test
vaginali
osom
sekisui
diagnost
fda
clear
use
pointofcar
test
femal
patient
test
specif
includ
sensit
specif
affirm
vpiii
microbi
identif
test
fdaclear
test
use
nonamplifi
na
probe
detect
three
organ
associ
vagin
vaginali
gardnerella
vaginali
candida
albican
sensit
specif
detect
vaginali
respect
naat
sensit
test
avail
detect
vaginali
varieti
ldt
naat
sensit
previou
goldstandard
test
cultur
rapid
analysi
time
current
two
fdaclear
naat
detect
vaginali
femal
patient
aptima
trichomona
vaginali
assay
hologicgenprob
detect
vaginali
rna
transcriptionmedi
amplif
sensit
specif
also
offer
opportun
test
vaginali
sampl
submit
ct
ng
test
aptima
combo
assay
test
run
platform
bd
probe
tec
tv
q
x
amplifi
dna
assay
detect
vaginali
use
strand
displac
amplif
viper
system
perform
characterist
similar
aptima
assay
test
ct
ng
also
perform
viper
system
laboratori
diagnosi
trichomoniasi
remain
challeng
particularli
men
consider
select
diagnost
method
includ
test
locat
analysi
time
perform
characterist
cost
perform
test
clinic
diagnosi
hsv
insensit
nonspecif
therefor
clinic
diagnosi
genit
herp
confirm
laboratori
test
mani
infect
person
experi
multipl
vesicular
ulcer
lesion
typic
genit
herp
virolog
typespecif
serolog
test
use
confirm
diagnosi
cell
cultur
naat
prefer
virolog
test
person
seek
diagnosi
treatment
genit
ulcer
mucocutan
lesion
sensit
viral
cultur
low
especi
recurr
lesion
declin
rapidli
lesion
begin
heal
naat
hsv
dna
increasingli
use
mani
laboratori
sever
test
clear
fda
anogenit
specimen
naat
prefer
test
detect
hsv
spinal
fluid
diagnosi
hsv
infect
cn
discuss
later
chapter
cultur
naat
determin
whether
infect
due
recurr
asymptomat
shed
much
less
frequent
genit
infect
failur
detect
hsv
cultur
naat
rule
hsv
infect
viral
shed
intermitt
use
tzanck
prepar
pap
test
detect
cytolog
chang
produc
hsv
insensit
nonspecif
use
genit
hsv
infect
serolog
test
detect
typespecif
nonspecif
antibodi
hsv
develop
first
sever
week
month
infect
persist
indefinit
typespecif
serolog
test
base
antigen
specif
commerci
avail
almost
infect
sexual
acquir
typespecif
antibodi
indic
anogenit
infect
howev
presenc
antibodi
distinguish
anogenit
orolabi
infect
typespecif
hsv
serolog
assay
might
use
follow
scenario
recurr
genit
symptom
atyp
symptom
neg
hsv
pcr
cultur
clinic
diagnosi
genit
herp
without
laboratori
confirm
patient
whose
partner
genit
herp
hsv
serolog
test
consid
person
present
sti
evalu
especi
person
multipl
sex
partner
person
hiv
infect
men
sex
men
increas
risk
hiv
acquisit
human
papillomavirus
small
doublestrand
dna
virus
infect
squamou
epithelium
subvert
normal
cell
growth
potenti
lead
squamou
cell
carcinoma
scc
hpv
singl
viru
famili
relat
viral
genotyp
distinguish
base
sequenc
analysi
region
viral
genom
anogenit
hpv
infect
common
men
women
estim
million
men
women
unit
state
current
infect
hpv
hpv
sti
common
among
sexual
activ
young
women
age
year
one
studi
cervicovagin
hpv
found
sexual
activ
colleg
women
period
infect
howev
usual
transient
progress
cancer
requir
persist
viral
infect
sever
year
type
hpv
spread
sexual
contact
classifi
low
high
risk
progress
malign
multipl
type
infect
lowrisk
hpv
type
lead
benign
genit
wart
condyloma
acuminata
low
likelihood
progress
malign
contrast
highrisk
type
type
associ
develop
scc
anogenit
region
oropharynx
current
highrisk
hr
hpv
type
recogn
cervix
particularli
affect
worldwid
cervic
scc
continu
caus
signific
morbid
mortal
cancer
death
product
infect
usual
result
cytolog
histolog
chang
includ
cellular
nuclear
enlarg
nuclear
hyperchromasia
perinuclear
halo
koilocytosi
chang
identifi
stain
smear
cell
collect
cervix
pap
smear
develop
dr
georg
papanicola
biopsi
taken
colposcopi
loop
electrosurg
excis
procedur
pap
smear
use
success
identifi
women
cervic
cancer
import
detect
precursor
lesion
biopsi
excis
perform
remov
lesion
earlier
diseas
process
metastasi
occur
introduct
liquid
cytolog
media
autom
cytolog
processor
procedur
appropri
call
pap
test
smear
longer
use
histolog
type
squamou
precursor
lesion
divid
three
categori
mild
dysplasia
cervic
intraepitheli
neoplasia
moder
dysplasia
sever
dysplasia
carcinoma
situ
bethesda
system
cytolog
classif
squamou
precursor
lesion
divid
lowand
highgrad
squamou
intraepitheli
lesion
lsil
hsil
lsil
correspond
hsil
correspond
frequent
cytolog
evalu
demonstr
mildli
atyp
cell
meet
criteria
refer
atyp
squamou
cell
undetermin
signific
ascu
cell
may
correspond
earli
hpv
infect
preval
ascu
pap
test
approxim
rate
high
report
sexual
activ
women
screen
cervic
cancer
cytolog
test
effect
reduc
cervic
cancer
unit
state
mani
year
approach
annual
pap
test
hybrid
captur
test
qiagen
digen
detect
hr
hpv
type
approv
fda
screen
women
ascu
detect
pap
test
determin
need
colposcopi
time
hybrid
captur
test
fdaapprov
test
avail
fda
approv
expand
use
test
includ
screen
preform
conjunct
pap
test
women
age
year
refer
cotest
cotest
allow
women
extend
test
interv
year
test
result
neg
fda
approv
use
hr
hpv
test
coba
hpv
test
roch
primari
cervic
cancer
screen
women
older
age
year
without
need
concomit
pap
test
use
hr
hpv
test
primari
screen
test
pap
test
perform
specif
hr
hpv
type
detect
exclud
colposcopi
perform
without
interven
pap
test
women
test
posit
algorithm
base
primarili
result
singl
larg
fda
registr
studi
coba
hpv
test
interim
clinic
guidanc
avail
use
primari
hr
hpv
test
cervic
cancer
screen
howev
still
consider
debat
whether
cotest
hr
hpv
primari
screen
test
optim
approach
cervic
cancer
screen
four
test
detect
hr
hpv
type
clear
fda
use
unit
state
test
cervista
hpv
hr
hologicgenprob
coba
hpv
test
roch
aptima
hpv
test
hologicgenprob
addit
two
differ
fdaclear
test
specif
identifi
hpv
type
cervista
type
aptima
avail
featur
test
compar
tabl
test
clear
fda
use
thinprep
preservcyt
liquidbas
cytolog
medium
holog
commonli
use
surepath
medium
bectondickinson
test
reli
hybrid
rna
probe
hpv
dna
follow
use
antibodi
captur
duplex
rnadna
hybrid
detect
chemiluminesc
signal
amplif
test
use
pool
rna
probe
span
entir
genom
specif
hr
hpv
type
specif
type
identifi
test
use
microtit
plate
format
perform
manual
semiautom
rapid
captur
system
qiagen
reagent
plate
handl
also
clear
use
digen
specimen
transport
media
stm
test
use
sever
larg
studi
reproduc
demonstr
high
sensit
falseposit
result
occur
result
crossreact
lowrisk
hpv
type
cervista
hpv
hr
assay
also
use
signal
amplif
method
base
cleavaseinvad
technolog
detect
highrisk
type
test
plu
type
combin
dna
probe
invad
oligonucleotid
target
sequenc
secondari
fluoresc
label
probe
divid
three
phylogenet
relat
reaction
perform
microtit
plate
unlik
assay
assay
includ
intern
control
reaction
assay
detect
limit
around
genom
copi
per
millilit
cervista
hpv
hr
assay
less
crossreact
lowrisk
type
studi
compar
two
assay
demonstr
concord
howev
cervista
test
may
poor
specif
compar
test
hr
hpv
cervista
genotyp
test
use
cleavaseinvad
technolog
coba
hpv
test
first
realtim
pcr
method
approv
fda
cervic
cancer
screen
use
multiplex
primer
hydrolysi
probe
assay
individu
detect
hpv
type
simultan
hr
hpv
type
use
differ
fluoresc
label
probe
assay
includ
detect
human
bglobin
gene
intern
control
extract
amplif
adequaci
coba
system
use
autom
beadbas
na
extract
pcr
assembl
sensit
specif
similar
cervista
hr
hpv
assay
current
fdaclear
test
indic
primari
screen
aptima
hpv
assay
target
viral
mrna
hpv
gene
hr
hpv
type
gene
hr
hpv
type
known
oncogen
protein
express
polycistron
mrna
alter
cellular
retinoblastoma
protein
function
lead
disrupt
cellcycl
check
point
genom
instabl
target
mrna
oncogen
element
may
effect
approach
detect
cervic
diseas
detect
hpv
genom
dna
aptima
hpv
assay
involv
three
main
step
take
place
singl
tube
target
captur
target
amplif
transcriptionmedi
amplif
detect
amplicon
hybrid
protect
assay
assay
also
incorpor
intern
control
monitor
na
captur
amplif
detect
well
oper
instrument
error
unlik
intern
control
use
cervista
roch
assay
assess
specimen
adequaci
cellular
adjunct
test
detect
differenti
hpv
type
base
principl
describ
also
avail
hologicgenprob
detect
emerg
respiratori
virus
requir
multipl
modal
molecular
method
crucial
discoveri
character
develop
diagnost
tool
acut
respiratori
viral
infect
lead
caus
hospit
death
infant
young
children
contribut
problem
asthma
exacerb
otiti
media
lower
respiratori
tract
infect
contribut
acut
diseas
immunocompromis
elderli
patient
rapid
diagnosi
aid
effect
treatment
eg
antivir
medic
oseltamivir
influenza
viru
infect
manag
eg
reduct
inappropri
prescrib
antibiot
viral
infect
infect
control
rapid
antigenbas
eia
provid
short
tat
minut
hamper
poor
diagnost
sensit
compar
cultur
method
molecular
assay
low
posit
predict
valu
especi
preval
low
direct
fluoresc
antibodi
dfa
detect
assay
viral
antigen
centrifug
cellular
materi
nasopharyng
swab
aspir
wash
specimen
demonstr
greater
rate
detect
rapid
antigen
assay
provid
result
rel
short
time
frame
hour
detect
rate
howev
lower
antigen
detect
method
naat
cell
cultur
method
although
slower
antigen
detect
method
consid
gold
standard
detect
wide
rang
viral
pathogen
recent
year
cultur
method
optim
detect
combin
multipl
cell
line
improv
tat
week
day
use
shellvial
spin
amplif
cultur
patient
specimen
concentr
onto
cell
grown
coverslip
fluoresc
antibodi
detect
perform
hour
incub
instead
wait
develop
cytopath
effect
although
hasten
time
detect
day
still
requir
along
signific
technologist
labor
quit
sensit
molecular
method
detect
molecular
detect
respiratori
virus
offer
sever
advantag
tradit
virolog
cultur
antigen
detect
import
analyt
sensit
molecular
assay
primarili
use
pcr
realtim
pcr
consist
better
tradit
method
result
molecular
test
accur
thu
patient
benefit
appropri
treatment
decis
also
infect
control
practition
effect
implement
strategi
prevent
reduc
nosocomi
transmiss
molecular
assay
design
detect
wide
rang
viral
pathogen
includ
virus
difficult
cultur
despit
advantag
naat
respiratori
viru
detect
adopt
clinic
laboratori
initi
slow
limit
capac
realtim
pcr
assay
multiplex
numer
ldt
fdaclear
realtim
pcr
assay
capabl
detect
one
three
differ
virus
singl
reaction
provid
comprehens
coverag
respiratori
virus
panel
assay
need
deploy
approach
practic
laboratori
current
sever
fdaclear
multiplex
respiratori
viru
panel
capabl
detect
differ
viral
target
thu
provid
simplifi
approach
comprehens
diagnost
respiratori
virus
see
tabl
overview
import
paramet
respiratori
viru
panel
test
truli
transform
laboratori
replac
combin
limit
multiplex
naat
antigen
detect
test
culturebas
method
tradit
use
clinic
laboratori
detect
respiratori
virus
thu
dramat
increas
diagnost
yield
xtag
respiratori
viral
panel
rvp
assay
multiplex
rtpcrebas
assay
fluoresc
colorcod
microspher
bead
hybrid
simultan
detect
identif
respiratori
virus
subtyp
multiplex
rtpcr
primer
amplifi
conserv
region
virus
product
label
biotincontain
deoxynucleotid
second
targetspecif
primer
extens
reaction
extens
product
proprietari
tag
sequenc
incorpor
hybrid
virusspecif
probe
colorcod
bead
hybrid
phycoerythrinconjug
streptavidin
bound
biotinlabel
primer
extens
product
fluoresc
signal
quantifi
luminex
xmap
instrument
instrument
contain
two
laser
one
identif
microb
colorcod
bead
detect
phycoerythrin
signal
attach
primer
extens
product
data
record
mean
fluoresc
intens
softwar
analyz
data
report
posit
result
assay
includ
separ
lambda
phage
amplif
control
bacteriophag
intern
control
extract
amplif
origin
version
assay
modifi
reduc
number
step
analysi
time
rvpfast
includ
parainfluenza
virus
sensit
overal
predecessor
number
postpcr
process
step
version
test
care
must
taken
avoid
amplicon
crosscontamin
falseposit
result
biofir
diagnost
develop
pcr
instrument
call
filmarray
associ
reagent
pouch
togeth
capabl
simultan
detect
multipl
organ
sampl
filmarray
pouch
contain
freezedri
reagent
perform
na
purif
revers
transcript
nest
multiplex
pcr
follow
highresolut
melt
analysi
filmarray
respiratori
panel
rp
design
simultan
detect
identif
viral
bacteri
respiratori
pathogen
see
tabl
test
initi
load
water
unprocess
patient
nasopharyng
swab
specimen
mix
lysi
buffer
filmarray
rp
pouch
pouch
place
filmarray
instrument
softwar
simpl
interfac
requir
identif
specimen
pouch
barcod
initi
run
multiplex
twostag
rtpcr
follow
highresolut
melt
analysi
target
amplicon
use
detect
panel
analyt
result
report
hour
current
instrument
design
test
singl
sampl
per
run
though
multipl
instrument
link
complet
close
system
falseposit
result
caus
amplicon
crosscontamin
issu
esensor
system
genmark
dx
use
electrochemicaldetectionbas
dna
microarray
microarray
compos
print
circuit
board
consist
array
goldplat
electrod
electrod
modifi
multicompon
selfassembl
monolay
includ
presynthes
oligonucleotid
captur
probe
na
detect
base
sandwich
assay
principl
signal
captur
probe
design
sequenc
complementari
immedi
adjac
region
correspond
target
dna
sequenc
threememb
complex
form
captur
probe
target
sequenc
signal
probe
base
sequencespecif
hybrid
process
bring
end
signal
probe
contain
electrochem
activ
ferrocen
label
close
proxim
electrod
surfac
ferrou
ion
ferrocen
group
undergo
cyclic
oxid
reduct
lead
loss
gain
electron
measur
current
electrod
surfac
use
alternatingcurr
voltammetri
higherord
harmon
signal
analysi
also
facilit
discrimin
ferrocenedepend
farad
current
background
capacit
current
esensor
cartridg
consist
print
circuit
board
cover
microfluid
compon
microfluid
compon
includ
diaphragm
pump
check
valv
line
serpentin
channel
form
hybrid
channel
array
electrod
esensor
instrument
consist
base
modul
three
cartridgeprocess
tower
eight
slot
cartridg
cartridg
slot
oper
independ
throughput
threetow
system
reach
test
hour
respiratori
pathogen
panel
esensor
system
detect
differ
type
subtyp
respiratori
virus
see
tabl
fda
clear
test
requir
postpcr
manipul
sampl
care
must
taken
avoid
falseposit
test
caus
amplicon
crosscontamin
verigen
system
nanospher
use
pcr
amplif
gold
nanoparticlelabel
probe
detect
target
na
hybrid
captur
oligonucleotid
array
glass
slide
silver
signal
amplif
perform
gold
nanoparticl
probe
hybrid
captur
dna
target
interest
verigen
reader
optic
scan
slide
silver
signal
process
data
produc
qualit
result
test
detect
influenza
viru
influenza
viru
subtyp
influenza
viru
subtyp
influenza
b
rsv
subtyp
b
clear
fda
verigen
system
system
capabl
much
higherord
multiplex
respiratori
panel
detect
viral
bacteri
target
develop
avail
unit
state
ruo
product
molecular
test
respiratori
virus
like
continu
includ
test
design
detect
limit
number
virus
particular
import
eg
influenza
b
virus
rsv
well
test
detect
broad
array
virus
clinic
need
type
test
use
comprehens
respiratori
viru
panel
greatli
increas
diagnost
yield
abil
detect
mix
viral
infect
howev
clinic
signific
mix
infect
well
document
understood
addit
test
option
rang
simpl
sampl
answer
system
complex
test
requir
multipl
manual
step
meet
differ
nich
variou
clinic
laboratori
set
fact
pointofcar
molecular
test
respiratori
virus
possibl
recent
develop
cliawaiv
test
influenza
b
virus
aler
deliv
result
minut
perform
nonlaboratori
personnel
perform
characterist
similar
naat
perform
laboratori
mycobacterium
tuberculosi
caus
wide
rang
clinic
infect
includ
pulmonari
diseas
miliari
tuberculosi
mening
pleurisi
pericard
periton
gi
diseas
genitourinari
diseas
lymphaden
tuberculosi
infect
steadi
declin
unit
state
alltim
low
late
number
report
case
began
increas
resurg
relat
aid
epidem
homeless
decreas
focu
tuberculosi
control
program
infect
rate
continu
rise
foreignborn
person
result
immigr
countri
high
preval
tuberculosi
infect
increas
tuberculosi
infect
focus
consider
attent
develop
assay
rapid
diagnosi
molecular
method
center
effort
convent
test
laboratori
confirm
tuberculosi
includ
acidfast
bacilli
afb
smear
microscopi
produc
result
hour
cultur
requir
week
produc
result
although
rapid
inexpens
afb
smear
microscopi
limit
poor
sensit
cultureconfirm
pulmonari
tuberculosi
case
poor
posit
predict
valu
tuberculosi
set
nontubercul
mycobacteria
commonli
isol
compar
afb
smear
microscopi
ad
valu
naat
includ
greater
posit
predict
valu
afb
smearposit
specimen
nontubercul
mycobacteria
common
abil
rapidli
confirm
presenc
tuberculosi
smearneg
cultureposit
specimen
compar
cultur
naat
detect
presenc
tuberculosi
specimen
week
earlier
patient
suspect
pulmonari
tuberculosi
ultim
confirm
cultur
advantag
impact
patient
care
tuberculosi
control
effort
avoid
unnecessari
contact
investig
respiratori
isol
patient
whose
afb
smearposit
specimen
contain
tuberculosi
cdc
recommend
naat
perform
least
one
prefer
first
respiratori
specimen
patient
suspect
pulmonari
tuberculosi
diagnosi
tuberculosi
consid
yet
establish
test
result
would
alter
case
manag
tuberculosi
control
activ
naat
also
use
inform
decis
discontinu
airborn
infect
isol
precaut
health
care
set
naat
replac
need
cultur
patient
suspect
tuberculosi
specimen
collect
mycobacteri
cultur
current
two
fdaapprov
naat
avail
direct
detect
tuberculosi
clinic
specimen
amplifi
mycobacterium
tuberculosi
direct
test
mtd
test
hologicgenprob
xpert
mtbrif
assay
cepheid
mtd
test
base
transcriptionmedi
amplif
ribosom
rna
use
test
afb
smearposit
smearneg
respiratori
specimen
xpert
mtbrif
assay
use
realtim
pcr
detect
dna
tuberculosi
mutat
rpob
gene
associ
rifampin
resist
sputum
specimen
rifampin
resist
often
coexist
isoniazid
resist
detect
rifampin
resist
serv
marker
potenti
multidrugresist
tuberculosi
strain
similar
assay
develop
cepheid
xpert
mtbrif
assay
use
dispos
cartridg
autom
na
extract
target
amplif
amplicon
detect
conjunct
genexpert
instrument
system
sensit
specif
xpert
mtbrif
assay
detect
tuberculosi
appear
compar
fdaapprov
naat
use
sensit
detect
rifampin
resist
specif
multicent
studi
use
archiv
prospect
specimen
subject
suspect
tuberculosi
preval
rifampin
resist
low
unit
state
posit
result
indic
mutat
rpob
gene
confirm
rapid
dna
sequenc
prompt
reassess
treatment
regimen
follow
growthbas
drug
suscept
test
cdc
offer
servic
free
charg
genu
bordetella
compos
eight
speci
four
caus
respiratori
diseas
human
b
bronchiseptica
b
holmesii
b
parapertussi
b
pertussi
whoop
cough
pertussi
highli
contagi
respiratori
diseas
caus
b
pertussi
despit
widespread
childhood
vaccin
case
report
unit
state
http
report
case
repres
tip
iceberg
estim
million
case
occur
unit
state
annual
although
pertussi
occur
often
children
younger
year
age
incid
older
children
increas
substanti
recent
year
adolesc
adult
immun
wane
sever
year
prior
infect
vaccin
transmit
organ
suscept
infant
pertussi
older
children
adult
usual
character
prolong
cough
without
inspiratori
whoop
posttuss
vomit
typic
observ
infant
b
parapertussi
may
respons
pertussislik
diseas
often
young
children
ill
gener
milder
caus
b
pertussi
b
bronchiseptica
infrequ
caus
diseas
human
usual
occur
immunocompromis
individu
case
usual
exposur
farm
anim
pet
serv
natur
host
b
bronchiseptica
b
holmesii
recent
recogn
speci
associ
pertussislik
ill
human
four
speci
play
signific
role
human
respiratori
diseas
consid
design
naat
patient
pertussislik
diseas
laboratori
diagnosi
pertussi
fundament
transform
past
decad
cultur
dfa
stain
nasopharyng
secret
larg
replac
naat
clinic
laboratori
although
cultur
specif
diagnosi
rel
insensit
fastidi
natur
slow
growth
b
pertussi
make
difficult
isol
although
dfa
stain
provid
rapid
result
neither
sensit
specif
serolog
test
use
late
diseas
organ
may
detect
cultur
naat
investig
outbreak
test
standard
result
may
difficult
interpret
naat
import
tool
diagnosi
pertussi
enhanc
sensit
rapid
turnaround
compar
cultur
consid
standard
care
give
falseposit
falseneg
result
discuss
later
varieti
ldt
primarili
base
realtim
pcr
differ
perform
characterist
deploy
clinic
laboratori
current
two
fdaapprov
naat
b
pertussi
one
standalon
test
base
loopmedi
amplif
meridian
bioscienc
part
respiratori
panel
biofir
diagnost
number
differ
gene
target
use
naat
bordetella
spp
share
among
differ
speci
naat
base
detect
multicopi
insert
sequenc
increas
sensit
test
valid
target
b
pertussi
also
found
b
holmesii
b
bronchiseptica
therefor
test
base
target
alon
limit
valu
particularli
use
outbreak
set
found
b
parapertussi
b
bronchiseptica
b
holmesii
found
b
pertussi
parapertussi
b
holmesii
bronchiseptica
multiplex
pcr
target
three
iss
may
allow
detect
differenti
major
pathogen
infect
human
b
pertussi
b
parapertussi
b
holmesii
number
assay
base
singl
copi
gene
target
also
describ
promot
region
pertussi
toxin
operon
often
use
diagnost
assay
howev
also
present
b
parapertussi
b
bronchiseptica
mutat
promot
region
express
found
b
holmesii
mutat
promot
region
found
b
parapertussi
b
bronchiseptica
exploit
realtim
pcr
assay
use
postamplif
analysi
melt
temperatur
distinguish
amplicon
differ
speci
pertactin
filament
hemagglutinin
adenyl
cyclas
rec
flagellin
gene
sequenc
also
share
among
differ
speci
gene
target
report
specif
b
pertussi
except
pertussi
toxin
gene
none
singl
gene
target
extens
valid
diagnost
assay
posit
predict
valu
naat
remain
biggest
challeng
test
detect
b
holmesii
b
bronchiseptica
clinic
epidemiolog
purpos
consid
biolog
falseposit
result
environment
contamin
b
pertussi
dna
patient
clinic
identifi
sourc
pseudooutbreak
diseas
posit
predict
valu
naat
b
pertussi
increas
amplifi
gene
target
share
speci
use
multiplex
assay
twotier
approach
confirm
posit
creat
indetermin
rang
assay
target
multicopi
iss
segreg
clean
dirti
area
clinic
laboratori
test
symptomat
patient
guidanc
health
care
profession
use
interpret
naat
b
pertussi
found
cdc
websit
http
wwwcdcgovpertussisclinicaldiagnostictestingdiagnosispcrbestpracticeshtml
one
import
function
clinic
microbiolog
laboratori
detect
bloodstream
infect
use
convent
growbas
system
blood
cultur
system
signal
posit
typic
within
hour
incub
pathogen
blood
cultur
broth
gram
stain
subcultur
solid
medium
coloni
grow
medium
identif
antimicrobi
suscept
test
perform
typic
take
addit
hour
complet
blood
cultur
signal
posit
direct
inocul
convent
identif
suscept
test
use
posit
blood
cultur
broth
reduc
time
requir
obtain
result
elimin
subcultur
solid
medium
practic
fda
approv
autom
identif
suscept
test
system
varieti
nabas
test
develop
expedit
identif
organ
posit
blood
cultur
fdaapprov
test
includ
peptid
na
fluoresc
situ
hybrid
pna
fish
probe
realtim
pcr
assay
detect
singl
limit
number
pathogen
highord
multiplex
blood
cultur
identif
panel
base
nest
pcr
gold
nanoparticl
microarray
matrixassist
laser
desorpt
ioniz
timeofflight
mass
spectrometri
malditof
use
proteom
rather
genom
identifi
pathogen
base
mass
spectrum
protein
found
microorgan
appli
direct
identif
microorgan
posit
blood
cultur
bottl
key
featur
method
list
tabl
pna
fish
probe
dna
probe
neg
charg
sugar
phosphat
backbon
replac
noncharg
peptid
backbon
result
rapid
bind
dna
target
electrostat
repuls
target
pna
fish
probe
avail
rapid
identif
staphylococcu
aureu
coagulaseneg
staphylococci
enterococcu
faecali
enterococci
escherichia
coli
klebsiella
pneumonia
pseudomona
aeruginosa
candida
albican
andor
c
parapsilosi
c
tropicali
c
glabrata
andor
c
krusei
advandx
recent
protocol
involv
approxim
minut
handson
time
minut
result
access
fluoresc
microscop
special
filter
requir
read
stain
slide
number
laboratorydevelop
naat
direct
identif
singl
limit
number
organ
directli
blood
cultur
describ
gener
gain
widespread
accept
clinic
laboratori
number
commerci
avail
assay
applic
also
limit
aureu
bacteremia
requir
prompt
microbiolog
diagnosi
appropri
antibiot
administr
vancomycin
standard
treatment
suspect
aureu
bacteremia
center
isol
methicillinresist
aureu
mrsa
howev
less
effect
methicillin
treat
methicillinsuscept
aureu
mssa
strain
therefor
surpris
mani
method
rapid
identif
bloodstream
pathogen
focus
differenti
mrsa
mssa
two
fdaapprov
realtim
pcr
assay
detect
differenti
mrsa
mssa
directli
posit
blood
cultur
bd
geneohm
staphsr
bd
diagnost
xpert
mrsa
sa
bc
cepheid
assay
assay
limit
accur
differenti
mrsa
mssa
larg
assay
design
select
gene
target
see
chapter
section
antibacteri
drug
resist
detail
two
highord
multiplex
assay
approv
fda
identif
microorgan
blood
cultur
bottl
verigen
gramposit
gramneg
blood
cultur
test
nanospher
filmarray
blood
cultur
identif
bcid
panel
biofir
diagnost
organ
antibiot
resist
gene
includ
panel
list
box
filmarray
bcid
panel
use
technolog
respiratori
panel
describ
previous
detect
genusor
speciesspecif
target
includ
gramposit
gramneg
bacteria
candida
spp
thee
antibiot
resist
gene
approxim
hour
panel
identifi
posit
blood
cultur
provid
import
inform
resist
methicillin
staphylococci
vancomycin
resist
enterococci
carbapenemas
product
enter
gramneg
rod
verigen
bcid
panel
use
nanogold
microarray
technolog
identifi
organ
posit
blood
cultur
bottl
without
na
amplif
gramposit
gramneg
panel
chosen
base
result
gram
stain
perform
bottl
signal
posit
gramposit
panel
detect
genusor
speciesspecif
target
antibiot
resist
gene
gramneg
panel
detect
genusor
speciesspecif
target
antibiot
resist
gene
hour
minim
handson
time
gramposit
panel
detect
meca
vana
vanb
gene
gramneg
panel
detect
six
differ
blactamas
gene
verigen
yeast
blood
cultur
panel
develop
includ
c
albican
c
dubliniensi
c
glabrata
c
krusei
c
parapsilosi
c
tropicali
c
gattii
cryptococcu
neoforman
filmarray
verigen
panel
provid
comprehens
approach
rapid
identif
vast
major
blood
pathogen
import
inform
suscept
pathogen
antibiot
coupl
activ
antimicrobi
stewardship
program
intervent
result
test
like
posit
impact
clinic
outcom
patient
sepsi
method
discuss
preced
section
provid
opportun
expedit
identif
microorgan
blood
cultur
signal
posit
repres
signific
advanc
howev
blood
cultur
requir
day
incub
posit
timelin
inconsist
need
obtain
rapid
answer
inform
treatment
decis
patient
sepsi
direct
detect
pathogen
blood
without
need
cultur
would
ideal
present
number
challeng
specimen
prepar
enrich
pathogen
dna
integr
frontend
specimen
prepar
backend
molecular
analysi
identifi
virtual
pathogen
major
obstacl
success
also
highli
sensit
molecular
method
direct
detect
microbi
dna
blood
present
signific
challeng
valid
given
known
limit
sensit
cultur
current
gold
standard
roch
septifast
system
avail
longer
method
direct
detect
microorgan
blood
use
realtim
pcr
perform
lightcycl
instrument
target
ribosom
intern
transcrib
spacer
region
target
dna
amplifi
three
parallel
multiplex
realtim
pcr
assay
detect
gramposit
gramneg
fungal
pathogen
melt
curv
analysi
use
reliabl
differenti
pathogen
assay
technic
complex
requir
larg
amount
handson
time
analysi
time
hour
sever
evalu
report
lower
sensit
specif
clinic
set
compar
blood
cultur
anoth
molecular
approach
direct
detect
pathogen
blood
bodi
fluid
develop
ibi
bioscienc
subsidiari
abbott
molecular
method
combin
broadrang
pcr
electrospray
ioniz
timeofflight
mass
spectrometri
pcresim
technolog
describ
great
detail
elsewher
briefli
work
coupl
conservedsit
pcr
reaction
abl
amplifi
share
gene
divers
microorgan
esim
measur
amplicon
mass
provid
speciesspecif
signatur
match
known
signatur
databas
pcr
amplif
esim
analysi
perform
amplicon
mixtur
g
c
base
composit
compar
databas
known
base
composit
deriv
exist
sequenc
data
technolog
accur
identifi
divers
microb
blood
bodi
fluid
tissu
research
set
pcresim
system
evalu
direct
detect
bacteria
candida
spp
blood
patient
suspect
bloodstream
infect
found
sensit
specif
compar
cultur
replic
test
discrep
sampl
pcresim
result
increas
sensit
specif
confirm
infect
consid
true
posit
ibisabbott
develop
autom
integr
platform
pcresm
analysi
clinic
sampl
call
iridica
bloodstream
infect
assay
new
platform
identifi
differ
organ
four
antibiot
resist
gene
current
clinic
trial
anoth
novel
technolog
show
promis
direct
detect
pathogen
blood
magnet
reson
ebas
biosens
biosystem
develop
assay
directli
identifi
candida
spp
blood
patient
suspect
candidemia
assay
candida
cell
lyse
dna
amplifi
pcr
amplifi
product
detect
directli
wholeblood
matrix
ampliconinduc
agglomer
superparamagnet
nanoparticl
nanoparticl
cluster
yield
chang
spinspin
relax
time
make
detect
magnet
reson
small
portabl
instrument
rapid
precis
relax
measur
design
standard
pcr
tube
instrument
autom
step
assay
approxim
minut
hand
time
result
avail
within
hour
candida
panel
fda
approv
clinic
trial
data
show
overal
sensit
specif
respect
biosystem
panel
develop
direct
detect
bacteria
blood
herp
simplex
viru
type
produc
variou
clinic
syndrom
involv
skin
eye
cn
genit
tract
although
na
test
use
detect
hsv
dna
clinic
manifest
discuss
focus
use
hsv
pcr
diagnosi
cn
infect
na
amplif
test
wide
view
standard
care
diagnosi
herp
simplex
viru
caus
enceph
mening
adult
wherea
hsv
enceph
usual
attribut
infect
hsv
type
hsv
mening
commonli
caus
hsv
type
hsv
enceph
sever
infect
high
morbid
mortal
treatment
acyclovir
reduc
mortal
rate
approxim
untreat
infect
neurolog
impair
common
surviv
hsv
enceph
may
reflect
primari
infect
reactiv
latent
infect
hsv
mening
usual
selflimit
diseas
resolv
cours
sever
day
without
therapi
patient
diseas
may
recur
lymphocyt
mening
period
year
neonat
hsv
infect
occur
deliveri
unit
state
commonli
acquir
intrapartum
contact
infect
matern
genit
secret
usual
hsv
type
newborn
three
gener
present
diseas
known
skin
eye
mouth
diseas
account
approxim
infect
enceph
account
dissemin
diseas
account
dissemin
diseas
often
associ
neurolog
diseas
cn
diseas
occur
newborn
neonat
hsv
infect
herp
simplex
viru
enceph
distinguish
clinic
enceph
caus
virus
west
nile
viru
st
loui
enceph
viru
eastern
equin
enceph
viru
histor
gold
standard
diagnosi
hsv
enceph
requir
brain
biopsi
identif
hsv
cell
cultur
immunohistochem
stain
approach
provid
high
sensit
specif
requir
invas
procedur
sever
day
elaps
result
avail
viral
cultur
cerebrospin
fluid
csf
sensit
less
diagnosi
hsv
enceph
adult
test
measur
hsv
antigen
antibodi
csf
diagnost
sensit
diagnost
specif
limit
convent
method
interest
assess
clinic
util
pcr
detect
hsv
dna
csf
patient
enceph
two
largest
studi
compar
hsv
pcr
csf
specimen
versu
brain
biopsi
patient
suspect
hsv
enceph
sensit
specif
pcr
greater
sensit
hsv
pcr
decreas
significantli
day
start
therapi
pcr
posit
earli
cours
ill
usual
within
first
hour
symptom
individu
hsv
dna
persist
csf
week
therapi
initi
clinic
util
hsv
pcr
also
establish
diagnosi
neonat
hsv
infect
one
studi
hsv
dna
detect
csf
infant
cn
diseas
dissemin
infect
infant
skin
eye
mouth
diseas
persist
hsv
dna
csf
newborn
longer
week
therapi
initi
associ
poor
outcom
base
find
detect
hsv
dna
csf
pcr
becom
standard
care
diagnosi
hsv
enceph
neonat
hsv
infect
newborn
dissemin
diseas
hsv
dna
may
detect
serum
plasma
specimen
use
diagnost
newborn
possibl
lumbar
punctur
although
sensit
hsv
pcr
high
neg
pcr
test
result
may
rule
neurolog
diseas
caus
hsv
particularli
pretest
probabl
high
situat
import
consid
repeat
test
hsv
enceph
hsv
mening
distinguish
clinic
viral
meningitid
although
recurr
viral
mening
strong
clue
hsv
may
etiolog
agent
unlik
hsv
enceph
hsv
mening
subject
larg
studi
evalu
clinic
util
pcr
diagnosi
nonetheless
sensit
viral
cultur
csf
specimen
hsv
pcr
csf
commonli
use
evalu
mening
describ
accur
anecdot
report
sever
molecular
test
detect
hsv
dna
genit
specimen
clear
fda
one
simplexa
hsv
direct
kit
focu
diagnost
clear
use
csf
specimen
sever
compani
provid
primer
probe
asr
use
compon
ldt
molecular
test
often
design
detect
hsv
type
equal
sensit
distinguish
hsv
type
may
necessari
clinic
manag
cn
diseas
infect
primer
use
detect
hsv
dna
commonli
target
polymeras
glycoprotein
b
glycoprotein
thymidin
kinas
gene
import
primer
amplifi
dna
herpesvirus
associ
neurolog
diseas
includ
cytomegaloviru
varicella
zoster
viru
human
herp
viru
type
epsteinbarr
viru
herp
simplex
viru
pcr
assay
need
low
detect
limit
sever
hundr
copi
per
millilit
specimen
use
evalu
neurolog
diseas
particularli
true
diagnosi
mening
csf
concentr
dna
tend
lower
seen
enceph
hsv
neurolog
diseas
rare
occur
individu
without
increas
csf
white
blood
cell
count
protein
concentr
caution
exercis
appli
gener
immunocompromis
individu
may
mount
typic
inflammatori
respons
hsv
infect
although
hsv
pcr
csf
specimen
clearli
gold
standard
diagnosi
neurolog
diseas
result
interpret
caution
neither
sensit
specif
test
result
alway
interpret
within
context
clinic
present
patient
result
correl
clinic
impress
repeat
test
perform
day
later
initi
neg
pcr
result
occur
small
notabl
number
patient
confirm
hsv
enceph
enterovirus
ev
divers
group
singlestrand
rna
virus
belong
picornavirida
famili
current
human
ev
divid
seven
speci
ev
rhinovirus
c
ev
speci
contain
virus
formerli
refer
coxsackievirus
ev
poliovirus
echovirus
genu
parechoviru
pev
compris
differ
serotyp
origin
thought
echovirus
although
genom
organ
similar
ev
origin
pev
uncertain
numer
clinic
present
seen
ev
pev
infect
includ
acut
asept
mening
enceph
exanthem
conjunct
acut
respiratori
diseas
gi
diseas
myopericard
sepsislik
syndrom
neonat
diagnos
typic
base
clinic
present
naat
viru
cultur
method
sever
drawback
includ
requir
inocul
multipl
cell
line
singl
cell
line
optim
ev
type
inabl
grow
ev
type
cell
cultur
limit
diagnost
sensit
cell
cultur
long
tat
day
ev
grow
cell
cultur
long
tat
cultur
mean
result
rare
avail
time
frame
influenc
clinic
manag
naat
offer
sever
import
advantag
cell
cultur
includ
improv
sensit
tat
result
na
test
consid
new
gold
standard
diagnosi
asept
mening
neonat
sepsi
syndrom
caus
ev
pev
infect
two
method
use
detect
enterovir
rna
clinic
specimen
rtpcr
na
sequence
base
amplif
primer
use
clinic
test
commonli
target
highli
conserv
urt
genom
detect
poliovirus
ev
primer
detect
parechovirus
although
virus
caus
asept
mening
gener
molecular
assay
good
detect
limit
rang
tissu
cultur
infecti
dose
tcid
per
test
assay
quit
specif
sequenc
similar
may
allow
amplif
type
rhinovirus
current
two
test
detect
ev
csf
specimen
clear
fda
nuclisen
easyq
enteroviru
xpert
ev
cepheid
howev
nuclisen
easi
q
ev
assay
longer
commerci
avail
xpert
ev
test
sensit
specif
diagnosi
enterovir
mening
xpert
test
advantag
simpl
perform
specimen
reagent
ad
cartridg
insert
instrument
na
extract
amplif
detect
fulli
autom
result
avail
within
hour
system
permit
random
access
allow
ondemand
test
nucleic
acid
test
diagnosi
enterovir
infect
evalu
varieti
clinic
studi
test
show
sensit
equal
greater
cell
cultur
high
specif
faster
tat
cell
cultur
sever
studi
suggest
use
molecular
method
diagnosi
enterovir
infect
infant
pediatr
patient
lead
overal
cost
save
reduc
use
antibiot
imag
studi
maxim
benefit
patient
care
cost
save
test
avail
daili
basi
mention
earlier
mani
ev
molecular
assay
detect
rhinovirus
detect
poliovirus
two
factor
lead
unexpect
mislead
posit
result
respiratori
stool
specimen
test
diagnosi
ev
mening
base
test
csf
specimen
sepsi
syndrom
best
diagnos
neonat
test
serum
plasma
csf
sampl
clostridium
difficil
gramposit
sporeform
anaerob
bacillu
frequent
found
stool
flora
healthi
infant
rare
found
stool
flora
healthi
adult
children
older
month
organ
acquir
ingest
spore
surviv
gastric
acid
barrier
germin
colon
alter
intestin
flora
use
antibiot
facilit
colon
intestin
tract
colon
patient
may
develop
symptom
diarrhea
coliti
strain
c
difficil
make
two
toxin
toxin
toxin
b
regulatori
protein
tcdr
tcdc
control
express
toxin
tcda
b
tcdb
gene
toxin
respons
symptomat
diseas
strain
lack
toxin
gene
caus
diarrhea
coliti
toxin
b
may
import
product
diseas
toxin
detect
toxin
activ
essenti
diagnost
test
c
difficileeassoci
diseas
addit
toxin
binari
toxin
describ
strain
c
difficil
recent
report
suggest
strain
encod
binari
toxin
cdt
delet
tcdc
gene
lead
overexpress
toxin
b
ribotyp
caus
outbreak
sever
diseas
c
difficil
frequent
caus
antibioticassoci
diarrhea
coliti
hospit
commun
hospit
risk
infect
increas
length
hospit
stay
use
antimicrobi
therapi
greatli
increas
likelihood
acquir
c
difficil
coliti
c
difficil
caus
spectrum
diseas
rang
asymptomat
carrier
state
fulmin
relaps
fatal
coliti
diarrhea
may
mild
sever
pseudomembran
coliti
classic
present
c
difficil
diseas
toxic
megacolon
may
also
seen
although
clindamycin
penicillin
cephalosporin
commonli
associ
diseas
almost
antibiot
caus
similar
diseas
variou
nonna
test
avail
diagnosi
c
difficil
infect
cultur
organ
alon
help
diagnosi
need
confirm
organ
produc
toxin
cell
cultur
cytotox
test
neutral
assay
ccna
detect
cytopath
effect
toxin
b
consid
gold
standard
diagnosi
clinic
import
c
difficil
infect
test
highli
sensit
specif
labor
intens
technic
demand
tat
day
limit
clinic
util
commonli
use
test
eia
later
flow
devic
detect
toxin
toxin
b
overal
test
lower
sensit
specif
cytotox
test
gener
eia
detect
toxin
b
prefer
strain
may
produc
toxin
altern
test
approach
detect
common
antigen
glutam
dehydrogenas
gdh
test
distinguish
toxigen
nontoxigen
strain
use
alon
diagnosi
c
difficil
diseas
posit
result
need
confirm
cytotox
test
toxin
eia
naat
detect
toxin
b
gene
gdh
test
use
screen
test
high
neg
predict
valu
one
studi
evalu
twostep
approach
use
gdh
test
initi
screen
follow
ccna
antigenposit
specimen
confirm
presenc
toxin
neg
antigen
test
result
predict
neg
ccna
limit
approach
delay
obtain
result
long
tat
ccna
test
recent
multistep
algorithm
use
gdh
toxin
eia
naat
deploy
clinic
laboratori
view
limit
tradit
method
molecular
test
good
altern
diagnosi
c
difficil
infect
first
naat
detect
c
difficil
stool
approv
time
write
differ
platform
fda
approv
avail
test
use
varieti
method
includ
realtim
pcr
loopmedi
amplif
helicasedepend
amplif
microarray
technolog
platform
design
lowvolum
laboratori
ondemand
test
other
amen
highvolum
batch
mode
test
assay
detect
varieti
gene
target
includ
tcda
tcdb
cdt
delet
tcdc
latter
two
surrog
identif
ribotyp
strain
although
naat
replac
method
clinic
laboratori
diagnosi
c
difficil
infect
high
neg
predict
valu
analyt
clinic
sensit
concern
specif
posit
predict
valu
detect
colon
well
infect
mention
earlier
laboratori
implement
multistep
diagnost
test
algorithm
use
gdh
toxin
eia
naat
howev
algorithm
con
complic
delay
final
result
may
reimburs
may
ultim
less
cost
effect
naat
alon
regardless
laboratori
choos
deploy
naat
test
limit
patient
diarrhea
increas
pretest
probabl
diseas
thu
help
mitig
concern
detect
patient
asymptomat
colon
toxigen
strain
infecti
gastroenter
ige
lead
caus
global
morbid
mortal
diarrheal
diseas
disproport
affect
develop
nation
ige
remain
signific
problem
industri
countri
well
year
approxim
million
case
ige
occur
unit
state
result
hospit
death
ige
associ
divers
array
etiolog
agent
includ
bacteria
virus
parasit
clinic
present
littl
aid
specif
etiolog
diagnosi
diarrhea
predomin
symptom
regardless
etiolog
accur
identif
etiolog
ige
provid
import
inform
impact
individu
patient
manag
infect
control
public
health
intervent
common
diagnost
practic
unit
state
requir
provid
choos
among
varieti
test
includ
antigen
detect
test
cultur
ova
parasit
microscop
examin
singletarget
naat
detect
respons
organ
toxin
addit
select
test
may
inform
patient
age
sever
diseas
immunocompromis
state
durat
type
diarrhea
travel
histori
time
year
often
clinician
unsur
pathogen
includ
test
consequ
may
miss
test
specif
pathogen
interest
laboratori
batteri
test
requir
detect
possibl
pathogen
labori
expens
maintain
requir
special
expertis
may
unaccept
long
tat
addit
convent
microbiolog
test
limit
sensit
mani
major
pathogen
applic
na
amplif
method
could
signific
impact
diagnosi
treatment
understand
epidemiolog
ige
time
write
five
fdaapprov
enter
pathogen
panel
comparison
key
featur
shown
tabl
system
use
varieti
differ
technolog
differ
number
type
target
includ
assay
overal
platform
design
throughput
prodess
prograstro
ssc
assay
hologicgenprob
use
realtim
pcr
detect
differenti
among
salmonella
spp
shigella
spp
campylobact
spp
well
shiga
toxin
shiga
toxin
gene
indic
shigatoxin
produc
e
coli
two
separ
master
mix
clostridium
difficil
c
difficileeassoci
diseas
spectrum
rang
mild
antibioticassoci
diarrhea
lifethreaten
toxic
megacolon
occur
hospit
commun
naat
detect
toxin
b
gene
c
difficil
sever
advantag
tradit
method
diagnosi
includ
increas
analyt
clinic
sensit
high
neg
predict
valu
decreas
analysi
time
concern
specif
posit
predict
valu
naat
led
laboratori
adopt
multistep
diagnost
algorithm
help
mitig
problem
detect
patient
asymptomat
colon
toxigen
strain
c
difficil
separ
na
extract
manual
pcr
setup
requir
bd
max
ebp
bd
diagnost
use
singl
realtim
pcr
master
mix
detect
essenti
pathogen
toxin
salmonella
spp
shigella
spp
enteroinvas
e
coli
campylobact
spp
howev
bd
max
autom
step
sampl
prepar
target
amplif
detect
system
develop
expand
panel
bacteria
detect
includ
viral
protozo
pathogen
luminex
xtag
gpp
use
multiplex
endpoint
pcr
liquid
bead
array
detect
differenti
eight
bacteria
three
virus
three
protozoa
includ
campylobact
spp
c
difficil
toxin
b
e
coli
enterotoxigen
e
coli
shigalik
toxin
produc
e
coli
salmonella
spp
shigella
spp
vibrio
cholera
adenoviru
noroviru
gigii
rotaviru
cryptosporidium
spp
entamoeba
histolytica
giardia
spp
system
provid
high
throughput
requir
separ
na
extract
step
postpcr
amplicon
manipul
lead
falseposit
result
caus
amplicon
carryov
crosscontamin
also
longest
analysi
time
avail
system
verigen
use
multiplex
pcr
gold
nanoparticl
microarray
detect
five
bacteria
two
toxin
two
virus
includ
campylobact
spp
salmonella
spp
shigella
spp
vibrio
spp
yersinia
enterocolitica
noroviru
rotaviru
simpl
use
sampl
answer
system
limit
throughput
one
sampl
per
instrument
run
time
filmarray
use
nest
multiplex
pcr
melt
curv
analysi
detect
bacteria
comprehens
enter
pathogen
panel
current
avail
similar
filmarray
product
simpl
use
provid
result
hour
chief
limit
low
throughput
high
cost
laboratori
choos
varieti
test
platform
base
whether
focus
broader
approach
ige
pathogen
detect
desir
also
technic
complex
requir
throughput
import
variabl
may
influenc
approach
chosen
applic
current
stool
test
algorithm
use
convent
method
typic
requir
clinician
consid
pathogen
might
associ
diseas
choos
among
varieti
test
ensur
pathogen
cover
surpris
piecem
approach
often
fail
yield
posit
result
use
comprehens
pathogen
panel
dramat
increas
diagnost
yield
come
uniqu
challeng
interpret
result
patient
multipl
pathogen
detect
fda
clinic
trial
filmarray
gi
panel
least
one
potenti
pathogen
detect
specimen
among
multipl
potenti
pathogen
detect
asymptomat
infect
c
difficil
cryptosporidium
spp
g
lamblia
uncommon
ige
pathogen
salmonella
spp
noroviru
shed
week
resolut
symptom
comprehens
panel
consolid
test
platform
agent
ige
substanti
reduc
complet
elimin
need
cultur
isol
need
epidemiolog
surveil
occasion
antibiot
suscept
test
detect
antibiot
resist
one
import
function
clinic
microbiolog
laboratori
tradit
done
phenotyp
method
howev
delay
inher
phenotyp
test
lead
delay
appropri
therapi
advers
clinic
outcom
molecular
method
offer
faster
altern
detect
antibiot
resist
genotyp
approach
set
challeng
complex
antibiot
resist
addit
detect
resist
gene
may
necessarili
impli
phenotyp
resist
gene
express
low
level
function
advanc
technolog
understand
genet
antibiot
resist
like
make
use
molecular
detect
antibiot
resist
widespread
futur
section
focus
commonli
use
resist
target
current
mrsa
vancomycinresist
enterococci
vre
blactamas
gramneg
bacteria
aureu
among
common
caus
bacteri
infect
industri
world
particular
attent
focus
assay
rapidli
differenti
mrsa
mssa
diagnosi
infect
surveil
infect
control
purpos
molecular
assay
recogn
mrsa
base
detect
singl
target
detect
junction
staphylococc
cassett
chromosom
mec
element
sccmec
carri
meca
resist
gene
flank
orfx
gene
assay
design
sever
limit
includ
falseneg
result
caus
sccmec
variant
falseposit
result
caus
mssa
strain
carri
sccmec
remnant
lack
meca
gene
sometim
refer
empti
cassett
carri
sccmec
nonfunct
meca
gene
altern
approach
molecular
detect
mrsa
combin
meca
target
second
gene
target
specif
aureu
nuc
femafemb
spa
time
write
five
compani
fdaapprov
assay
molecular
detect
mrsa
mrsa
mssa
bd
diagnost
cepheid
elitech
roch
addit
standalon
assay
molecular
detect
mrsa
incorpor
blood
cultur
identif
panel
discuss
previous
assay
intend
use
surveil
test
assist
diagnosi
infect
depend
platform
test
run
demand
batch
studi
indic
use
molecular
method
rapid
identif
patient
colon
mrsa
may
costeffect
infect
control
strategi
enterococci
commens
resid
gi
tract
femal
genit
tract
account
hospitalacquir
infect
vast
major
enterococc
infect
caus
enterococcu
faecali
e
faecium
occur
primarili
patient
requir
longterm
care
emerg
vre
hospit
concern
vancomycin
often
use
empir
treat
wide
varieti
infect
infect
vre
associ
increas
morbid
mortal
propens
vre
infect
patient
alreadi
high
risk
comorbid
unit
state
enterococci
resist
vancomycin
highlevel
vancomycin
resist
enterococci
occur
via
acquisit
mobil
transpos
element
carri
vana
vanb
gene
e
faecium
frequent
resist
vancomycin
e
faecali
vana
commonli
found
vanb
resist
strain
mrsa
rapid
detect
vre
colon
prevent
health
careeassoci
infect
wide
recommend
molecular
assay
work
well
applic
three
fdaapprov
molecular
assay
market
rapid
detect
vre
perian
rectal
swab
bd
geneohm
imdx
assay
detect
vana
vanb
cepheid
assay
detect
vana
alon
base
realtim
pcr
cepheid
assay
design
ondemand
test
asid
rare
report
vana
aureu
streptococcu
spp
detect
vana
highli
specif
vre
howev
vanb
found
wide
varieti
commens
nonenterococc
bacteria
detect
vanb
requir
confirm
vre
cultur
meca
assay
detect
vana
vanb
also
incorpor
commerci
avail
blood
cultur
identif
panel
one
greatest
threat
antibiot
formulari
emerg
blactamas
gramneg
bacteria
capabl
hydrolyz
broadspectrum
penicillin
cephalosporin
carbapenem
enzym
includ
extendedspectrum
blactamas
esbl
ampc
carbapenemas
accur
detect
zyme
import
treatment
decis
infect
control
purpos
detect
organ
harbor
broadspectrum
blactamas
phenotyp
method
imperfect
rapid
inexpens
multiplex
molecular
assay
detect
gene
encod
enzym
would
clinic
use
present
unmet
need
one
biggest
challeng
molecular
detect
great
divers
blactamas
describ
esbl
numer
class
carbapenemas
includ
k
pneumonia
carbapenemas
kpc
new
delhi
metalloblactamas
ndm
verona
integrinencod
metalloblactamas
vim
imipenem
metalloblactamas
imp
oxacillinas
oxa
addit
challeng
detect
gene
provid
inform
copi
number
express
import
phenotyp
express
resist
blactam
carbapenem
antibiot
number
ldt
ruo
kit
develop
molecular
detect
varieti
broadspectrum
blactamas
gene
rang
singl
target
assay
detect
kpc
highli
multiplex
assay
detect
multipl
esbl
multipl
ampc
kpc
ndm
vim
imp
biofir
filmarray
verigen
bcid
panel
includ
assay
detect
kpc
verigen
panel
detect
gene
encod
five
addit
broadspectrum
blactamas
ctxm
ndm
vim
imp
oxa
microbi
inhabit
outnumb
bodi
cell
genom
level
greater
gene
content
human
genom
interest
elucid
role
resid
organ
human
health
diseas
flourish
past
decad
advent
new
technolog
interrog
complex
microbi
commun
microbiom
total
microb
genet
inform
milieu
interact
includ
bacteria
fungi
virus
phage
parasit
emphasi
date
bacteri
compon
microbiom
howev
progress
made
toward
defin
human
virom
role
play
complex
microbi
commun
metagenom
refer
concept
collect
gene
sequenc
environ
could
analyz
way
analog
studi
singl
genom
facilit
advanc
na
sequenc
technolog
technolog
permit
studi
microbi
commun
directli
natur
environ
thu
bypass
need
isol
cultiv
individu
speci
know
major
microorgan
human
bodi
cultur
vitro
taxonom
metagenom
studi
use
target
sequenc
phylogenet
inform
region
rrna
gene
bacteria
long
gold
standard
method
bacteri
identif
larg
sequenc
databas
sophist
analysi
tool
avail
howev
rrna
gene
sequenc
provid
enough
inform
comprehens
microbiom
studi
overcom
limit
singl
genebas
amplicon
sequenc
research
use
wholegenom
shotgun
sequenc
massiv
parallel
sequenc
platform
wholegenom
approach
permit
identif
annot
divers
set
microbi
gene
encod
mani
differ
biochem
metabol
function
thu
provid
function
metagenom
inform
human
microbiom
project
launch
nation
institut
health
overarch
goal
develop
tool
resourc
character
human
microbiom
relat
human
health
diseas
initi
microbiom
comparison
across
differ
bodi
site
confirm
high
interindividu
variat
four
phyla
bacteria
actinobacteria
bacteroidet
firmicut
proteobacteria
predomin
across
bodi
site
addit
composit
gut
microbiom
often
character
smooth
abund
gradient
key
organ
cluster
individu
discret
microbiom
type
howev
microbiom
bodi
site
vagina
show
cluster
import
point
emerg
earli
studi
although
microbi
commun
vari
among
individu
metabol
pathway
encod
organ
consist
present
form
function
core
microbiom
bodi
site
although
pathway
process
core
consist
specif
gene
associ
function
vari
alter
microbiom
mani
differ
diseas
state
describ
complet
review
topic
beyond
scope
chapter
specif
exampl
given
tabl
establish
causal
link
microbiom
chang
specif
diseas
often
challeng
studi
observ
diseas
entiti
may
well
defin
pathogenesi
may
multifactori
howev
seem
clear
futur
approach
medic
microbiolog
shape
part
develop
metagenom
human
microbiom
research
identif
singl
agent
infect
supplement
techniqu
determin
rel
composit
microbiom
context
differ
infect
diseas
state
recent
evid
recurr
c
difficil
infect
treat
reconstitut
normal
colon
microbiota
patient
transfer
fece
normal
donor
good
exampl
better
understand
chang
microbiom
composit
lead
effect
treatment
option
differ
composit
microbiom
may
caus
contribut
noninfecti
diseas
may
offer
new
opportun
clinic
microbiolog
laboratori
impact
area
medicin
final
metagenom
techniqu
facilit
discoveri
previous
unrecogn
pathogen
increas
understand
chang
microbiom
may
contribut
infecti
diseas
molecular
microbiolog
continu
one
lead
growth
area
laboratori
medicin
number
applic
technolog
clinic
microbiolog
continu
increas
technolog
increasingli
deploy
clinic
laboratori
becom
less
technic
complex
thu
access
howev
ever
clinic
financi
outcom
data
need
justifi
use
often
expens
technolog
era
declin
reimburs
increas
cost
conscious
clinic
util
molecular
test
infecti
diseas
well
establish
gap
avail
fdaclear
approv
test
clinic
need
improv
howev
pend
enhanc
oversight
ldt
restrict
use
ruo
iuo
reagent
system
fda
could
limit
abil
laboratori
develop
test
meet
clinic
need
met
ivd
product
http
wwwfda
govdownloadsmedicaldevicesdeviceregulationandguid
although
consider
progress
made
recent
year
import
need
remain
unmet
includ
avail
intern
standard
traceabl
commut
calibr
use
assay
verif
valid
materi
wide
avail
improv
agreement
result
among
differ
test
aid
establish
clinic
util
anoth
need
continu
develop
effect
profici
test
program
help
ensur
result
molecular
test
reliabl
reproduc
among
laboratori
digit
pcr
next
advanc
evolut
quantit
pcr
method
digit
pcr
mani
applic
includ
detect
quantif
low
number
pathogen
sequenc
provid
lower
limit
detect
realtim
pcr
method
better
precis
low
concentr
oppos
rel
quantif
digit
pcr
provid
absolut
quantif
need
refer
standard
current
digit
pcr
use
research
tool
may
find
applic
clinic
laboratori
resolv
ambigu
result
obtain
quantit
realtim
pcr
assay
creat
accur
viral
refer
standard
technolog
becom
less
costli
great
extent
futur
molecular
microbiolog
depend
autom
mani
avail
test
labor
intens
much
labor
devot
tediou
sampl
process
method
sever
fulli
autom
system
molecular
diagnost
develop
highand
midvolum
laboratori
suffer
limit
test
menu
increas
access
molecular
test
simpl
afford
fulli
autom
random
access
platform
broad
test
menu
need
particularli
laboratori
lowand
midvolum
test
na
test
infecti
diseas
point
care
begin
enter
clinic
practic
develop
develop
countri
particularli
applic
requir
short
tat
set
central
laboratori
approach
feasibl
use
multiplex
nabas
assay
screen
atrisk
patient
panel
probabl
pathogen
remain
goal
molecular
microbiolog
sever
test
current
avail
success
date
limit
technic
complex
system
develop
simpl
multiparametr
technolog
key
provid
molecular
test
broad
diagnost
rang
provid
cultur
convent
method
syndrom
diagnosi
infecti
diseas
metagenom
studi
provid
new
insight
human
microbiom
alter
commun
microorgan
link
number
diseas
state
continu
decreas
cost
massiv
parallel
na
sequenc
increas
avail
necessari
bioinformat
tool
like
understand
human
microbiom
result
novel
microbiomefocus
diagnost
clinic
intervent
addit
massiv
parallel
sequenc
platform
enabl
metagenom
increasingli
use
epidemiolog
investig
new
pathogen
discoveri
